documentSection
dict | hasResults
bool 2
classes | protocolSection
dict |
|---|---|---|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Shenqi Sherong Pill"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Cervical Spondylotic Myelopathy"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 428,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy",
"nctId": "NCT06377072",
"orgStudyIdInfo": {
"id": "SHPL-W036-301",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Serious adverse events"
},
{
"measure": "Adverse events"
},
{
"measure": "Vital sign (systolic and diastolic blood pressure after 10-minute rest)"
},
{
"measure": "Vital sign (body temperature)"
},
{
"measure": "Vital sign (respiration)"
},
{
"measure": "Vital sign (heart rate）"
},
{
"measure": "Laboratory test indicator (blood routine)"
},
{
"measure": "Laboratory test indicator (liver function)"
},
{
"measure": "Laboratory test indicator (kidney function)"
},
{
"measure": "Laboratory test indicator (fasting glucose)"
},
{
"measure": "Laboratory test indicator (urine routine and urinary sediment count)"
},
{
"measure": "Laboratory test indicator (stool routine and occult blood)"
},
{
"measure": "Electrocardiogram(ECG) QT Interval"
},
{
"measure": "ECG QTc Interval"
},
{
"measure": "ECG QRS Interval"
},
{
"measure": "ECG PR Interval"
},
{
"measure": "Pathological sign (Hoffmann sign)"
},
{
"measure": "Pathological sign (Babinski sign)"
},
{
"measure": "Concomitant medication"
}
],
"primaryOutcomes": [
{
"measure": "Change in Modified Japanese Orthopaedic Association (mJOA) score"
}
],
"secondaryOutcomes": [
{
"measure": "Change in mJOA score"
},
{
"measure": "Change in sensation of mJOA score"
},
{
"measure": "Changes in pain or stiffness score for neck and shoulder"
},
{
"measure": "Change in chest tightness score"
},
{
"measure": "Changes in hand and arm numbness scores"
},
{
"measure": "Change in numbness (or pain) scores from the chest to the toes"
},
{
"measure": "Change in Motor dysfunction of the upper extremities of mJOA score"
},
{
"measure": "Proportion of participants with at least 1 grade decline in Nurick grades"
},
{
"measure": "Change in Traditional Chinese medicine (TCM) syndrome integrality"
},
{
"measure": "Change in TCM syndrome score"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Shanghai Hutchison Pharmaceuticals Limited"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-11"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "WARD"
}
]
},
"conditionsModule": {
"conditions": [
"Hematologic Cancer",
"CRS - Cytokine Release Syndrome"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Aims\n\n* To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications\n* Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Early Detection of Complications During Immunotherapy for Haematological Malignancy",
"nctId": "NCT06377059",
"orgStudyIdInfo": {
"id": "2024-RH-phase1-WARD",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "CRS"
}
],
"secondaryOutcomes": [
{
"measure": "Immune response"
},
{
"measure": "severe physiological deviations"
},
{
"measure": "clinical complications"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Rigshospitalet, Denmark"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Accelerated pacing"
},
{
"name": "Current standard of care"
}
]
},
"conditionsModule": {
"conditions": [
"Atrial Fibrillation",
"Permanent Atrial Fibrillation",
"Persistent Atrial Fibrillation",
"Pacemaker DDD",
"Paroxysmal Atrial Fibrillation"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to determine the effect of accelerated pacing (pacemaker lower rate programmed to 80bpm) compared to pacing at the standard programmed lower rate of 60bpm in symptomatic atrial fibrillation patients undergoing pace-and-ablate strategy with LBBAP.\n\nThe main question it aims to answer is:\n\n- To determine the effect of accelerated pacing on health-related quality of life compared to the current standard of care.\n\nSecondary questions it aims to answer are:\n\n* To study the acute hemodynamic effect of different (accelerated) pacing rates on pulmonary capillary wedge pressure, cardiac output and arterial blood pressure among atrial fibrillation patients undergoing pace-and-ablate strategy.\n* To study the long-term effects (at 6 months) of accelerated pacing compared to the current standard of care among atrial fibrillation patients undergoing pace-and-ablate strategy on:\n* NT pro BNP levels\n* device detected atrial fibrillation burden and daily activity\n* echocardiographic measurements (LVEF, left ventricular ejection fraction; LVEDD, left ventricular end- diastolic diameter; LVESD, left ventricular end-systolic diameter; LAVI left atrial volume index; diastolic parameters; strain"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Randomized, single center, prospective, single blinded, parallel group, pilot-trial.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PACE-AF",
"briefTitle": "Accelerated Pacing in Patients Undergoing Pace-and-ablate Strategy With LBBAP: a Randomized Controlled Pilot Trial",
"nctId": "NCT06377046",
"orgStudyIdInfo": {
"id": "NL86643.068.24",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The effect of accelerated pacing (lower programmed rate of 80 bpm) compared to pacing at the standard programmed rate of 60 bpm on health-related quality of life (HRQoL) in symptomatic AF patients undergoing pace-and-ablate strategy with LBBAP."
}
],
"secondaryOutcomes": [
{
"measure": "The acute hemodynamic effects of different (accelerated) pacing rates on pulmonary capillary wedge pressure (PCWP)."
},
{
"measure": "The acute hemodynamic effects of different (accelerated) pacing rates on cardiac output (CO)."
},
{
"measure": "The acute hemodynamic effects of different (accelerated) pacing rates on arterial blood pressure."
},
{
"measure": "The long-term effects of accelerated pacing on health-related quality of life based on the 36-item short form health survey (SF-36) among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on NTproBNP levels among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on device detected AF burden among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on device detected daily activity among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy."
},
{
"measure": "Palpitations experienced as a result of (accelerated) pacing."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Maastricht University Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-11"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Behavioral nudge"
}
]
},
"conditionsModule": {
"conditions": [
"Genetic Predisposition",
"Paraganglioma",
"Pheochromocytoma",
"ALS",
"Parkinson Disease",
"Polyneuropathies",
"Frontotemporal Dementia",
"Alzheimer Disease",
"Cardiomyopathy Non-ischemic",
"Thoracic Aortic Aneurysm"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "FACTORIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "HEALTH_SERVICES_RESEARCH",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Using the EHR to Advance Genomic Medicine Across a Diverse Health System",
"nctId": "NCT06377033",
"orgStudyIdInfo": {
"id": "10877980",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Rate of Genetic Testing"
}
],
"secondaryOutcomes": [
{
"measure": "Rate of Genetic Test Orders/Referrals"
},
{
"measure": "Rate of Patient Engagement"
},
{
"measure": "Rate of Pathogenic variants and VUS"
},
{
"measure": "Rate of Clinician actions"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Pennsylvania"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "PACT2"
}
]
},
"conditionsModule": {
"conditions": [
"PreDiabetes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Aurora",
"contacts": [
{
"email": "[email protected]",
"name": "Elizabeth Thomas, MD",
"phone": "303-808-2622",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "University of Colorado Anschutz Medical Campus",
"geoPoint": {
"lat": 39.72943,
"lon": -104.83192
},
"state": "Colorado",
"status": "RECRUITING",
"zip": "80045"
}
]
},
"descriptionModule": {
"briefSummary": "People living with prediabetes are advised to lose weight to prevent development of type 2 diabetes by participating in intensive lifestyle interventions (ILI's), such as PreventT2. The PreventT2 program focuses on a low-calorie diet for weight loss. However, many people find it difficult to stick to a low-calorie diet over the long-term. The identification of novel, effective and individualized dietary strategies to produce long-term weight loss is critically important in diabetes prevention. An ILI based on PreventT2 which considers individual preferences, allowing participants to choose among a variety of diets, may result in greater adherence to the diet than a standard PreventT2 intervention. ILIs also need to be available to individuals in a wide range of communities, including Americans living in rural communities, who experience higher rates of obesity and chronic disease, yet have less access to medical care, including programs for diabetes prevention. The investigators plan to develop and carry out a 16-week pilot and feasibility study of a group-based ILI program based on PreventT2 plus choice of dietary strategy (Prevention and Choice for Type2 , PACT2) delivered via videoconference to adults with prediabetes living in rural communities. Successful completion of this project will result in the refinement of an ILI that incorporates personal preferences and is tailored to individuals at high risk for type 2 diabetes living in rural areas where access to such interventions is limited."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "This is a single group pilot and feasibility study",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 24,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PACT2",
"briefTitle": "Prevention and Choice for Type 2",
"nctId": "NCT06377020",
"orgStudyIdInfo": {
"id": "23-2490",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Body weight"
}
],
"secondaryOutcomes": [
{
"measure": "Blood pressure"
},
{
"measure": "Physical activity"
},
{
"measure": "Energy intake"
},
{
"measure": "HbA1c"
},
{
"measure": "24 hr glucose levels"
},
{
"measure": "Dietary adherence"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "American Diabetes Association"
},
{
"name": "High Plains Research Network"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "University of Colorado, Denver"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-10-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-23"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "IOLMaster 700 (Carl Zeiss Meditec AG)"
},
{
"name": "Argos (Alcon Laboratories, Inc.)"
}
]
},
"conditionsModule": {
"conditions": [
"Cataract"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nakhon Si Thammarat",
"contacts": [
{
"email": "[email protected]",
"name": "Jakkrit.ju Juhong, MD.",
"phone": "0816773406",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Thailand",
"facility": "Walailak University",
"geoPoint": {
"lat": 8.43333,
"lon": 99.96667
},
"state": null,
"status": "RECRUITING",
"zip": "80160"
}
]
},
"descriptionModule": {
"briefSummary": "Cataract surgery represents a common surgical intervention, encompassing the extraction of the opaque natural crystalline lens, followed by the substitution with an artificial intraocular lens (IOL). To ascertain an IOL possessing optimal power, antecedent to the surgery, preoperative evaluations are conducted through the utilization of a biometric devices. Diverse categories of these instruments are accessible, each harnessing distinct optical methodologies or mathematical algorithms to ascertain the most fitting IOL power. The principal objective of this study was to evaluate the ocular biometry and the predictive precision outcome of a biometer that uses standard keratometry to the prediction accuracy of another biometer that uses Total Keratometry."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 142,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "85 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ORION",
"briefTitle": "Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION)",
"nctId": "NCT06377007",
"orgStudyIdInfo": {
"id": "WU66290",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Walailak individual grant",
"id": "WU66290",
"link": null,
"type": "OTHER_GRANT"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mean absolute prediction error"
}
],
"secondaryOutcomes": [
{
"measure": "Proportion of eyes with an absolute prediction error equal to or less than 0.25"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Walailak University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Air cleaner"
},
{
"name": "Sham air cleaner"
}
]
},
"conditionsModule": {
"conditions": [
"Chronic Obstructive Pulmonary Disease (COPD)"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Baltimore",
"contacts": [
{
"email": "[email protected]",
"name": "Wendy Lorizio",
"phone": "410-510-2449",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Maggie Maly",
"phone": "410-550-9527",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Johns Hopkins",
"geoPoint": {
"lat": 39.29038,
"lon": -76.61219
},
"state": "Maryland",
"status": null,
"zip": "21224"
}
]
},
"descriptionModule": {
"briefSummary": "This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 770,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "40 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Clean Air",
"briefTitle": "Multi-Center Clean Air Randomized Controlled Trial in COPD",
"nctId": "NCT06376994",
"orgStudyIdInfo": {
"id": "IRB00407311",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "1U24HL169566-01",
"link": "https://reporter.nih.gov/quickSearch/1U24HL169566-01",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "St. George's Respiratory Questionnaire (SGRQ)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Heart, Lung, and Blood Institute (NHLBI)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "JHSPH Center for Clinical Trials"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-09"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-09"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Hyaluronic acid injection"
},
{
"name": "Corticosteroid injection"
},
{
"name": "Placebo injection"
}
]
},
"conditionsModule": {
"conditions": [
"Shoulder Tendinitis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "La Roche-sur-Yon",
"contacts": [
{
"email": null,
"name": "Céline COZIC, Dr",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "CHD Vendée",
"geoPoint": {
"lat": 46.66667,
"lon": -1.43333
},
"state": null,
"status": null,
"zip": null
},
{
"city": "Nantes",
"contacts": [
{
"email": null,
"name": "Christelle DARRIEUTORT-LAFFITE, Dr",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "CHU Nantes",
"geoPoint": {
"lat": 47.21725,
"lon": -1.55336
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Multicentric, randomised study to compare the effectiveness on activity pain at 3 months of corticosteroid injection associated with hyaluronic acid with corticosteroids injection alone in patients with tendinopathy of the supraspinatus with clinical reevaluation at one, three and six months."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 132,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ACCTE",
"briefTitle": "Hyaluronic Acid in Shoulder Tendinopathy",
"nctId": "NCT06376981",
"orgStudyIdInfo": {
"id": "CHD23_0025",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Visual analog scale pain on activity ranging from 0 to 100 mm at month 3."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Centre Hospitalier Departemental Vendee"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-11"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "BioLogic Fusion"
}
]
},
"conditionsModule": {
"conditions": [
"Renal Dialysis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bologna",
"contacts": [
{
"email": null,
"name": "Annalisa Zucchelli, Prof.",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Annalisa Zucchelli, Prof.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione",
"geoPoint": {
"lat": 44.49381,
"lon": 11.33875
},
"state": "Emilia Romagna",
"status": "RECRUITING",
"zip": "40138"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:\n\n• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.\n\nA crossover design is used to compare treatments with or without the BioLogic Fusion function activated."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 56,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis",
"nctId": "NCT06376968",
"orgStudyIdInfo": {
"id": "BA-G-H-1604",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Post-dialysis body weight"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "B.Braun Avitum AG"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-29"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-22"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "High intensity interval exercise"
},
{
"name": "Focused ultrasound"
}
]
},
"conditionsModule": {
"conditions": [
"Insulin Resistance",
"Abdominal Obesity",
"Diabetes"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Obesity and diabetes share a common insulin resistance pathway and contribute to chronic hyperglycemia. Both high-intensity interval exercise (HIIE) and focused ultrasound (FUS) have been explored in the context of managing insulin resistance in diabetic individuals with abdominal obesity, though they operate through different mechanisms and have different implications."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "35 Years",
"minimumAge": "25 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "diabetic",
"briefTitle": "High Intensity Interval Versus Focused Ultrasound on Insulin Resistance in Diabetics With Abdominal Obesity",
"nctId": "NCT06376955",
"orgStudyIdInfo": {
"id": "IRB00014233-1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Body mass index"
},
{
"measure": "Waist circumference"
},
{
"measure": "Skin fold"
},
{
"measure": "Value of HbA1c and HOMA-IR hormone"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Badr University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-16"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Glycopyrronium"
},
{
"name": "Ipratropium"
},
{
"name": "Saline"
}
]
},
"conditionsModule": {
"conditions": [
"Subjects Undergoing Flexible Bronchoscopy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Chandigarh",
"contacts": null,
"country": "India",
"facility": "Bronchoscopy suite, PGIMER",
"geoPoint": {
"lat": 30.73629,
"lon": 76.7884
},
"state": null,
"status": null,
"zip": "160012"
}
]
},
"descriptionModule": {
"briefSummary": "No study has examined the role of inhaled glycopyrrolate on mucus secretion. We hypothesize that nebulized glycopyrrolate will improve bronchoscopy procedure by effectively suppressing airway mucus secretion, thereby decreasing cough, and thus improving patient comfort during bronchoscopy. In this study, we aim to compare the efficacy of nebulized glycopyrrolate versus nebulized ipratropium in suppression of cough during flexible bronchoscopy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1050,
"type": "ESTIMATED"
},
"phases": [
"PHASE2",
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "85 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "NAFCOF",
"briefTitle": "A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy",
"nctId": "NCT06376942",
"orgStudyIdInfo": {
"id": "Int/IEC/2024/SPL-5",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Cough count"
}
],
"secondaryOutcomes": [
{
"measure": "Operator-estimated airway secretion"
},
{
"measure": "Operator-rated secretions on a visual analogue scale (VAS)"
},
{
"measure": "Operator-rated cough intensity on a visual analogue scale (VAS)"
},
{
"measure": "Patient-rated comfort on a visual analogue scale (VAS)"
},
{
"measure": "Adverse reactions"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Post Graduate Institute of Medical Education and Research, Chandigarh"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-25"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-24"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "oral carbohydrate containing fluid"
}
]
},
"conditionsModule": {
"conditions": [
"Postoperative Nausea and Vomiting"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The correlation between preoperative oral carbohydrate intake and intraoperative random blood sugar and also the effect on postoperative nausea and vomiting."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "randomized controlled",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": null
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "9 Years",
"minimumAge": "3 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Oral Carbohydrates in Pediatric Surgery and Random Blood Glucose Level",
"nctId": "NCT06376929",
"orgStudyIdInfo": {
"id": "oralcarbohydrateinpediatric",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mean values of Intraoperative random blood sugar in mg/dl"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cairo University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-25"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Magnesium Sulfate 2 G"
},
{
"name": "Magnesium Sulfate 4 G"
},
{
"name": "Saline"
}
]
},
"conditionsModule": {
"conditions": [
"Tachycardia Atrial",
"Atrial Fibrillation",
"Atrial Flutter With Rapid Ventricular Response"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Oak Lawn",
"contacts": [
{
"email": "[email protected]",
"name": "Marc McDowell, PharmD",
"phone": "708-684-6230",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Advocate Christ Medical Center Emergency Department (ACMC ED)",
"geoPoint": {
"lat": 41.71087,
"lon": -87.75811
},
"state": "Illinois",
"status": null,
"zip": "60453"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 153,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ATRIUM",
"briefTitle": "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR",
"nctId": "NCT06376916",
"orgStudyIdInfo": {
"id": "IRB00110863",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Ventricular rate control"
}
],
"secondaryOutcomes": [
{
"measure": "Time to achieve goal HR (heart rate)"
},
{
"measure": "Rate of conversion"
},
{
"measure": "Incidence of hypotension"
},
{
"measure": "Change in heart rate"
},
{
"measure": "Clinical need for rescue medication administration"
},
{
"measure": "Adverse effects"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Aurora Health Care"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-24"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Pilates exercise - pelvic floor exercise - home advices"
}
]
},
"conditionsModule": {
"conditions": [
"Urinary Stress Incontinence"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "• This study will be conducted to determine the effect of pilates exercises on stress urinary incontinence in postmenopausal women"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "50 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effect of Pilates Exercises on Stress Urinary Incontinence in Posmenopausal Women",
"nctId": "NCT06376903",
"orgStudyIdInfo": {
"id": "P.T.REC/012/004860",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "• Revised urinary incontinence scale"
}
],
"secondaryOutcomes": [
{
"measure": "• Quality of Life Questionnaire (QOL) for stress urinary incontinence"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cairo University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-22"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Red chili peppers"
},
{
"name": "Green Chili Pepper"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Prediabetes"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Diabetes is a major health epidemic facing the United States and New Mexico. Currently, 11.6% of the US population (38.4 million) has diabetes, and 38.0% of US adults have prediabetes. It is estimated that around 70% of prediabetics will develop diabetes in their lifetime. In New Mexico, 48% of adults are at least prediabetic, and 12% of adults in southern New Mexico adults have diabetes. Moreover, major health disparities challenge the southern New Mexico region. Type 2 diabetes mellitus (T2DM) is generally linked with chronic inflammation, obesity, insulin resistance, and ultimately insulin dependence via pancreatic β-cell failure. Lessening pathological inflammation, a critically important factor that contributes to diabetes, can improve the disease. Furthermore, 89.8% of diabetics in the US are overweight or obese, this is a major risk for prediabetes and T2DM, as it causes insulin resistance and pancreatic β-cell dysfunction, Weight loss in people with T2DM and prediabetes has been demonstrated to affect glycemic control and metabolic parameters significantly. The purpose of this proposed study is to explore and establish the beneficial effects of 10 weeks of powdered chili pepper consumption on several parameters related to diabetes and prediabetes. This research will demonstrate how powdered chili pepper consumption can improve systemic inflammation, glycemic control, and body composition, and will provide valuable preliminary data for future funding to further examine these effects in Type 2 diabetics. This research is innovative because chili peppers are an already widely accepted food in Southern New Mexico. Demonstrating the beneficial improvements in diabetes-related markers using a popular food in the area may help to establish better treatments and protocols for an area that has health disparities. The first aim is to establish if 10 weeks of powdered red or green chili pepper consumption can significantly improve markers of inflammation, inflammatory capacity, and antioxidant capacity. The second aim is to establish if 10 weeks of powdered red or green chili pepper ingestion has a significant effect on resting blood glucose and insulin levels, connecting peptide (C-peptide) levels, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). The third aim is to determine whether powdered chili pepper consumption for 10 weeks improves resting body composition and metabolic rate. This research is innovative because chili peppers are an already widely accepted food in Southern New Mexico. Demonstrating the beneficial improvements in diabetes-related markers using a popular food in the area may help to establish better treatments and protocols for an area with health disparities. Overall, this study will provide valuable insight and background knowledge for the use of chili peppers for the treatment of prediabetes and the prevention of diabetes progression."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A 3x2 model with 2 intervention groups (green and red chili) and a control group, and pre and post-intervention measures will be taken.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "Only the primary investigator will know the intervention assigned to the participants.",
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 21,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effects of Chili Pepper on Inflammation and Glycemic Control in Southern New Mexico",
"nctId": "NCT06376890",
"orgStudyIdInfo": {
"id": "Chile24",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Concentration of resting and fasted blood glucose measured in mg/dl"
},
{
"measure": "Concentration of resting and fasted insulin measured in pmol/L"
},
{
"measure": "Concentration of circulating C-reactive protein reported as mg/dl."
},
{
"measure": "Concentration of circulating interleukin (IL)-1 beta reported as pg/ml."
},
{
"measure": "Concentration of circulating interleukin-6 (IL-6) reported as pg/ml."
},
{
"measure": "Concentration of circulating interleukin tumor necrosis factor (TNF)-alpha reported as pg/ml."
}
],
"secondaryOutcomes": [
{
"measure": "Concentration of circulating superoxide dismutase (SOD) reported as ng/ml."
},
{
"measure": "Concentration of circulating glutathione peroxidase reported as pg/ml."
},
{
"measure": "Body composition measured as total fat mass and total fat free mass reported in kg."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "New Mexico State University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-07"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Transcranial magnetic stimulation"
},
{
"name": "Sham transcranial magnetic stimulation"
}
]
},
"conditionsModule": {
"conditions": [
"Anxiety Disorders",
"Mental Disorder",
"Psychiatric Disorder"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Boston",
"contacts": [
{
"email": "[email protected]",
"name": "Emma Jones",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Emma Jones",
"geoPoint": {
"lat": 42.35843,
"lon": -71.05977
},
"state": "Massachusetts",
"status": null,
"zip": "02115"
}
]
},
"descriptionModule": {
"briefSummary": "We will perform a randomized sham-controlled trial of aiTBS to an anxiosomatic circuit in patients with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder). 80 participants with an anxiety-related disorder (defined below) will receive 50 active or sham TMS treatments over 5 days (following the SAINT protocol, which is FDA-cleared for MDD. The primary outcome will be the BAI, with a modified recall window to reflect the short treatment interval. Participants randomized to sham will be offered an open-label crossover extension."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Nonresponders may have the option for open label active treatment.",
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ConTRA",
"briefTitle": "Connectomic Targeted TMS Target for Refractory Anxiety",
"nctId": "NCT06376877",
"orgStudyIdInfo": {
"id": "2024P000900",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Beck Anxiety Inventory (BAI)"
}
],
"secondaryOutcomes": [
{
"measure": "Inventory of Depression and Anxiety Symptoms-II"
},
{
"measure": "Hierarchical Taxonomy of Psychopathology (HiTOP)-Self Report, Distress, Fear, and Mania subfactors"
},
{
"measure": "State-Trait Anxiety Inventory"
},
{
"measure": "Penn State Worry Questionnaire (PSWQ)"
},
{
"measure": "Mood/Anxiety Symptoms Questionnaire: Anxious Arousal (MASQ:AA)"
},
{
"measure": "Anxiety Sensitivity Index (ASI)"
},
{
"measure": "Intolerance of Uncertainty Scale (IUS)"
},
{
"measure": "Beck Depression Inventory (BDI)"
},
{
"measure": "TCI-R140 (Temperament and character inventory, revised 140-question format)"
},
{
"measure": "Emotional Conflict Resolution Task"
},
{
"measure": "Laboratory Fear Extinction Paradigm"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Brigham and Women's Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-02-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-08-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-08-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Activity Breaks"
}
]
},
"conditionsModule": {
"conditions": [
"Child Behavior"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Kowloon Tong",
"contacts": null,
"country": "Hong Kong",
"facility": "Department of Sport, Physical Education, and Health, Hong Kong Bapist University",
"geoPoint": {
"lat": 22.33312,
"lon": 114.17969
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The current study aims to implement the Activity Breaks intervention and evaluate its effectiveness on outcome measures of executive function (EF), physical activity (PA), and sedentary behaviour (SB) in school children."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 450,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "12 Years",
"minimumAge": "8 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Physical Activity Intervention Effects on Executive Function, Physical Activity and Sedentary Behaviour in Children",
"nctId": "NCT06376864",
"orgStudyIdInfo": {
"id": "RC- FNRA-IG /20-21/SOSC/01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Executive function"
},
{
"measure": "Psychological capacities"
},
{
"measure": "Working memory"
},
{
"measure": "Attention"
}
],
"secondaryOutcomes": [
{
"measure": "Physical activity (min/week)"
},
{
"measure": "Sedentary behavior (hour)"
},
{
"measure": "Body weight (kg)"
},
{
"measure": "Height (cm)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hong Kong Baptist University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "AI-enabled quantitative coronary plaque analysis (AI-QCPA)"
}
]
},
"conditionsModule": {
"conditions": [
"Coronary Artery Disease"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Greensboro",
"contacts": null,
"country": "United States",
"facility": "Moses Cone Memorial Hospital",
"geoPoint": {
"lat": 36.07264,
"lon": -79.79198
},
"state": "North Carolina",
"status": null,
"zip": "27401"
}
]
},
"descriptionModule": {
"briefSummary": "The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA)."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 10000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "DECIDE",
"briefTitle": "AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management",
"nctId": "NCT06376851",
"orgStudyIdInfo": {
"id": "CP-910-001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Number of MACE (CV-related death, MI, or CAD hospitalization)"
},
{
"measure": "Timing of referral to other provider(s) for management"
},
{
"measure": "Timing of lab orders (Group 1 vs. Group 2)"
},
{
"measure": "Change in Lp(a) (Group 2)"
},
{
"measure": "Change in Lp(a) (Group 4 compared to Group 1)"
}
],
"primaryOutcomes": [
{
"measure": "Primary Endpoint"
}
],
"secondaryOutcomes": [
{
"measure": "Change in LDL levels"
},
{
"measure": "Change in HbA1c levels"
},
{
"measure": "Changes in Non HDL levels"
},
{
"measure": "Changes in HDL levels"
},
{
"measure": "Changes in TG levels"
},
{
"measure": "Changes in weight"
},
{
"measure": "Reclassification rate of medical management (across the groups)"
},
{
"measure": "Rates of referral to invasive coronary angiography and coronary revascularization (PCI+CABG)"
},
{
"measure": "Number of CV hospitalizations"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "HeartFlow, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-03-27"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2026-03-27"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-27"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "DLMR01"
},
{
"name": "Rejuran"
}
]
},
"conditionsModule": {
"conditions": [
"Crow's Feet Lines"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Seoul",
"contacts": null,
"country": "Korea, Republic of",
"facility": "Chung-ang University Hospital",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": "Dongjak-gu",
"status": null,
"zip": "06973"
}
]
},
"descriptionModule": {
"briefSummary": "This clinical study is a confirmatory clinical study to prove that the test device, DLMR01, is non-inferior to the control device, Rejuran®, in terms of temporary wrinkle improvement effect on crow's feet and safety. After applying DLMR01, a test device, and Rejuran®, a control device, respectively to wrinkles around the eyes, randomization to compare and evaluate the temporary wrinkle improvement effect and safety of the two clinical study medical devices, subject-evaluator blinding, pair matching, It was designed as a comparative clinical study."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 218,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "19 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "dermal filler",
"briefTitle": "To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet",
"nctId": "NCT06376838",
"orgStudyIdInfo": {
"id": "DLV-001-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Crow's Feet Grading Scale by independent evaluators after 12 weeks of using"
}
],
"secondaryOutcomes": [
{
"measure": "(1) The improvement rate of wrinkles evaluated using the Crow's Feet Grading Scale"
},
{
"measure": "(2) The improvement rate of wrinkles assessed using the Crow's Feet Grading Scale by independent evaluators after 2 weeks and 4 weeks of using the medical device both during rest and when smiling was evaluated."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "DEXLEVO"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-05-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2021-10-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-07-07"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "MyLife: An internet-based self-help program to reduce burnout"
}
]
},
"conditionsModule": {
"conditions": [
"Burnout, Professional"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": [
{
"email": "[email protected]",
"name": "Eda Aksoy",
"phone": "+90(216) 269 66 11",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Ahmet Nalbant, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Havvanur Uysal Akdemir, MS",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Edanur Gürbüz, BA",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Meryem Gökçe Yavuz, BA",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Kaasım Fatih Yavuz, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Turkey",
"facility": "CanSagligi Foundation Center for Contextual Behavioral Science",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to determine whether an internet-based self-help program reduces burnout in teachers. The study will also evaluate the program's acceptability which means assessing the extent to which users complete the program and find it useful. The main questions it aims to answer are:\n\n* Does the program reduce the level of burnout in teachers?\n* Does the program contribute to an increased sense of meaning for teachers?\n* How much of the program do teachers finish?"
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "The study will be a concurrent multiple-baseline single-case experimental study with participiants randomized to baseline durations.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "In this study participants will be randomized to different baseline durations and randomization will be done by one of the investigators who are blind to participants assessments.",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 25,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "22 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Efficacy and Acceptability of an Internet-Based Self-Help Program to Reduce Burnout",
"nctId": "NCT06376825",
"orgStudyIdInfo": {
"id": "CSV202401",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Daily measures"
}
],
"primaryOutcomes": [
{
"measure": "Burnout Assessment Tool"
},
{
"measure": "Valued Living Questionnaire"
}
],
"secondaryOutcomes": [
{
"measure": "Acceptance and Action Questionnaire-2"
},
{
"measure": "System Usability Scale"
},
{
"measure": "Attendance rate"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ahmet Nalbant"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-06-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Physical activity intervention"
}
]
},
"conditionsModule": {
"conditions": [
"Elevated Blood Pressure",
"Perimenopause"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This study will test the effects of a physical activity intervention among midlife Hispanic women."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "50 Years",
"minimumAge": "45 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women",
"nctId": "NCT06376812",
"orgStudyIdInfo": {
"id": "23-0320",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Abdominal circumference"
},
{
"measure": "Abdominal circumference"
},
{
"measure": "Body mass index"
},
{
"measure": "Body mass index"
}
],
"primaryOutcomes": [
{
"measure": "Days the activity monitor was worn"
}
],
"secondaryOutcomes": [
{
"measure": "Physical activity as measured by minutes of moderate-vigorous intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of moderate-vigorous intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of moderate intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of moderate intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of vigorous intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of vigorous intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of light intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of light intensity physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of total physical activity at 6 months"
},
{
"measure": "Physical activity as measured by minutes of total physical activity at 6 months"
},
{
"measure": "Systolic blood pressure"
},
{
"measure": "Systolic blood pressure"
},
{
"measure": "Diastolic blood pressure"
},
{
"measure": "Diastolic blood pressure"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "The University of Texas Medical Branch, Galveston"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2026-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Self-questionnaire"
}
]
},
"conditionsModule": {
"conditions": [
"Advance Care Planning",
"Patient Preference"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this descriptive observational study is to evaluate the preference of French adult patients followed in the context of a oncological disease, regarding the choice of the preferred healthcare professional to discuss advance care planning.\n\nTo this end, voluntary participants will be asked to indicate their preferences by answering a self-questionnaire available in electronic or paper format."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 240,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "QPSPAS",
"briefTitle": "Which Health-care Professional(s) to Talk About Advance Care Planning ?",
"nctId": "NCT06376799",
"orgStudyIdInfo": {
"id": "38RC23.0437",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "ID RCB",
"id": "2024-A00485-42",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Determining the healthcare professional preferred by cancer patients to talk about advance care planning"
}
],
"secondaryOutcomes": [
{
"measure": "Determining cancer patients' second choice of healthcare professional to talk about advance care planning"
},
{
"measure": "Evaluation of patient preferences regarding advance care planning, concerning the form, the moment it should be carried out, whether or not they wish to be accompanied by a relative, and the benefit of systematization"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospital, Grenoble"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-11-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-11-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"TTP - Thrombotic Thrombocytopenic Purpura"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in Italy.\n\nA minimum of 132 consecutive patients with acute iTTP (first event or relapse) will be enrolled for 3 years, with the possibility of extension, with a follow-up period of 3 years."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 132,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "99 Years",
"minimumAge": "12 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Italian iTTP Registry",
"nctId": "NCT06376786",
"orgStudyIdInfo": {
"id": "ItaliTTP",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Age at onset"
},
{
"measure": "Sex"
},
{
"measure": "Birth Country/Region"
},
{
"measure": "Race"
},
{
"measure": "Blood group"
},
{
"measure": "BMI"
},
{
"measure": "Proportion of patients with comorbidities, including: autoimmune diseases, cancer, HIV infection, hypertension, type 2 diabetes, hypercholesterolemia, cardiovascular disease, chronic renal failure, liver disease, depression."
},
{
"measure": "Proportion of acute iTTP episodes preceded by potential triggering factors including: infections, pregnancy, surgery, psychological trauma, vaccination, drugs"
},
{
"measure": "Incidence, type and severity of clinical manifestations, including: bleeding, cardiovascular, neurological, renal and systemic signs and symptoms"
},
{
"measure": "Platelet count lactate dehydrogenase (LDH), total and indirect bilirubin, liver transaminases, creatinine, troponin"
},
{
"measure": "Hemoglobin lactate dehydrogenase (LDH), total and indirect bilirubin, liver transaminases, creatinine, troponin"
},
{
"measure": "Lactate dehydrogenase (LDH) lactate dehydrogenase (LDH), total and indirect bilirubin, liver transaminases, creatinine, troponin"
},
{
"measure": "Creatinine lactate dehydrogenase (LDH), total and indirect bilirubin, liver transaminases, creatinine, troponin"
},
{
"measure": "Cardiac troponin"
},
{
"measure": "ADAMTS13 activity"
},
{
"measure": "Anti-ADAMTS13 antibodies"
},
{
"measure": "Number of daily therapeutic plasma exchange procedures"
},
{
"measure": "Proportion of acute iTTP patients treated with rituximab"
},
{
"measure": "Proportion of acute iTTP patients treated with immunosuppressors other than steroids and rituximab"
},
{
"measure": "Proportion of iTTP patients treated with caplacizumab"
},
{
"measure": "Incidence, type and severity of TTP-related drugs adverse events"
},
{
"measure": "Proportion of iTTP patients achieving clinical remission"
},
{
"measure": "Proportion of iTTP patients refractory to acute iTTP treatment"
},
{
"measure": "Proportion of iTTP patients experiencing complications during hospitalization, including: bleeding, thrombosis, neurological, renal, cardiac complications"
},
{
"measure": "Proportion of iTTP patients experiencing clinical exacerbation"
},
{
"measure": "Proportion of iTTP patients achieving ADAMTS13 remission"
},
{
"measure": "Time to clinical response"
},
{
"measure": "Time to clinical remission"
},
{
"measure": "Time to ADAMTS13 remission"
},
{
"measure": "Proportion of iTTP patients with a clinical relapse"
},
{
"measure": "Proportion of iTTP patients with an ADAMTS13 relapse"
},
{
"measure": "Time to clinical relapse"
},
{
"measure": "Time to ADAMTS13 relapse"
},
{
"measure": "Incidence, type and severity of pregnancy complications in iTTP pregnant women"
}
],
"secondaryOutcomes": [
{
"measure": "iTTP incidence in Italy"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Fondazione Luigi Villa"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-05-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2030-05-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "combination chemotherapy with Apatinib or Camrelizumab"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Gastric Cancer",
"Neoadjuvant Therapy",
"Multi-omics Analysis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Fuzhou",
"contacts": null,
"country": "China",
"facility": "Fujian Medical University Union Hospital",
"geoPoint": {
"lat": 26.06139,
"lon": 119.30611
},
"state": "Fujian",
"status": null,
"zip": "350000"
}
]
},
"descriptionModule": {
"briefSummary": "Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 234,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.",
"nctId": "NCT06376773",
"orgStudyIdInfo": {
"id": "2022KY123",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "overall survival"
}
],
"secondaryOutcomes": [
{
"measure": "objective response rate"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Fujian Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-11-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "No interventions, it is a observational study"
}
]
},
"conditionsModule": {
"conditions": [
"Insomnia",
"Digestive Endoscopy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": "[email protected]",
"name": "Fang Luo, M.D.",
"phone": "13611326978",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Fang Luo, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "China",
"facility": "Beijing Tiantan Hospital",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": null,
"zip": "100070"
}
]
},
"descriptionModule": {
"briefSummary": "To compare the dosage requirement of intravenous anesthetics during digestive endoscopy between patients with insomnia and those with normal sleep pattern."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 3360,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "64 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Changes in Intravenous Anesthetic Drug Dosage in Insomnia Patients Undergoing Digestive Endoscopy",
"nctId": "NCT06376760",
"orgStudyIdInfo": {
"id": "KY2024-091-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The total consumption of intravenous anesthetic drug"
}
],
"secondaryOutcomes": [
{
"measure": "The dosage of intravenous anesthetic drug for successful insertion of digestive endoscope"
},
{
"measure": "The occurrence of the respiratory and cardiovascular adverse events"
},
{
"measure": "The occurrence of the other adverse events"
},
{
"measure": "The incidence of intraoperative recall or awareness"
},
{
"measure": "The recovery time"
},
{
"measure": "Duration of patients' PACU stay"
},
{
"measure": "The ease of operation at this level of sedation evaluated by the gastroenterologists"
},
{
"measure": "The satisfaction degree of anesthesia effect evaluated by the gastroenterologists"
},
{
"measure": "Patients' satisfaction"
},
{
"measure": "Patients' willingness"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Beijing Tiantan Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-03-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "In line sampling"
},
{
"name": "Standard blood sampling technique"
}
]
},
"conditionsModule": {
"conditions": [
"Iatrogenic Anaemia"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Brno",
"contacts": null,
"country": "Czechia",
"facility": "KDAR - department of pediatrics anesthesia and resuscitation",
"geoPoint": {
"lat": 49.19522,
"lon": 16.60796
},
"state": null,
"status": null,
"zip": "62500"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this prospective randomized study is to evaluate blood loss caused by laboratory blood draws in patients in the paediatric ICU (Intensive Care Unit) of a tertiary hospital among two groups of patients with established long-term or mid-term intravenous access. In the first group, patients will undergo blood draws using the standard method. In the second group of patients, blood draws will be performed using a closed system."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "Patients will be randomized into two groups: a group with standard blood sampling technique and a group with closed technique blood sampling by using randomizing software.",
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "19 Years",
"minimumAge": "1 Month",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": "PEDPBM",
"briefTitle": "The Influence of Blood Sampling Technique on the Total Amount of Blood Collected for Laboratory Testing Critically Ill Pediatric Patients",
"nctId": "NCT06376747",
"orgStudyIdInfo": {
"id": "KDAR- PBM 2024",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Average amount of blood collected for laboratory diagnostic purposes"
}
],
"secondaryOutcomes": [
{
"measure": "Cumulative amount of blood drawn per day of ICU hospitalization"
},
{
"measure": "Absolute amount of blood drawn and blood used for laboratory testing"
},
{
"measure": "Trend of haemoglobin decline over time"
},
{
"measure": "Incidence of anaemia"
},
{
"measure": "Incidence of anaemia up to transfusion trigger"
},
{
"measure": "Frequency of blood product transfusions and their quantity"
},
{
"measure": "Type and frequency of laboratory tests"
},
{
"measure": "Incidence of coagulopathy"
},
{
"measure": "Incidence of catheter-related complications"
},
{
"measure": "Time to catheter replacement in case of catheter exchange"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Brno University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-08-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "TMS"
}
]
},
"conditionsModule": {
"conditions": [
"Major Depressive Disorder",
"Obsessive-Compulsive Disorder",
"Schizophrenia",
"Generalized Anxiety Disorder",
"Mood Disorders",
"Psychiatric Disorder",
"Mental Disorder",
"Depression, Anxiety"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "Double-blind, randomized controlled crossover trial. Participants will be stimulated at a random location in the prefrontal cortex, which will be mapped to its underlying brain network to determine which network was stimulated.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "All participants will receive real open-label TMS, so there will be no conventional masking. However, participants and investigators will be blinded to which network is being stimulated.",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 180,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "Searchlight",
"briefTitle": "Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness",
"nctId": "NCT06376734",
"orgStudyIdInfo": {
"id": "2024p000528",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Clustering of multiple behavioral measures"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Institutes of Health (NIH)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Brigham and Women's Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Linperlisib"
},
{
"name": "Camrelizumab"
},
{
"name": "Pegaspargase"
},
{
"name": "Dexamethasone"
}
]
},
"conditionsModule": {
"conditions": [
"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",
"T-lymphoblastic Lymphoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Beijing",
"contacts": [
{
"email": "[email protected]",
"name": "Liang Wang, M.D.",
"phone": "+8615001108693",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Liang Wang, M.D.",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "China",
"facility": "Liang Wang",
"geoPoint": {
"lat": 39.9075,
"lon": 116.39723
},
"state": "Beijing",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Treatment with linperlisib in combination with camrelizumab and pegaspargase for advanced or relapsed/refractory ENKTCL patients",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 43,
"type": "ESTIMATED"
},
"phases": [
"PHASE1",
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma",
"nctId": "NCT06376721",
"orgStudyIdInfo": {
"id": "TREC2024-KY016",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Drug safety"
}
],
"primaryOutcomes": [
{
"measure": "The best objective response rate（ORR） over 6 treatment cycles"
}
],
"secondaryOutcomes": [
{
"measure": "Objective Response Rate（ORR）"
},
{
"measure": "Complete Response （CR）"
},
{
"measure": "Progression Free Survival (PFS)"
},
{
"measure": "Overall Survival (OS)"
},
{
"measure": "Disease Control Rate（DCR）"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Beijing Tongren Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-10-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-14"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "platelet rich fibrin"
},
{
"name": "Polyether ether ketone"
}
]
},
"conditionsModule": {
"conditions": [
"Maxillary Sinus"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cairo",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of Dentistry Cairo University",
"geoPoint": {
"lat": 30.06263,
"lon": 31.24967
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "comparison between the resulted bone during maxillary sinus elevation by PEEK with and without platelet rich fibrin"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "use of platelet rich fibrin after maxillary sinus elevation using PEEK",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 24,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "50 Years",
"minimumAge": "20 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Comparison Between PEEK With Platelet-rich Fibrin and PEEK Alone in Maxillary Sinus Augmentation",
"nctId": "NCT06376708",
"orgStudyIdInfo": {
"id": "3-3-13",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Bone quantity"
}
],
"secondaryOutcomes": [
{
"measure": "Bone quality"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Cairo University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-03-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Radicle GI Health Placebo Control Form 1"
},
{
"name": "Radicle GI Health Active Study Product 1.1 Usage"
}
]
},
"conditionsModule": {
"conditions": [
"Abdominal Pain",
"GI Disorders",
"Digestion"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Del Mar",
"contacts": null,
"country": "United States",
"facility": "Radicle Science, Inc",
"geoPoint": {
"lat": 32.95949,
"lon": -117.26531
},
"state": "California",
"status": null,
"zip": "92014"
}
]
},
"descriptionModule": {
"briefSummary": "A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on GI health and related health outcomes"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Participants will be stratified based on gender at birth then randomized to one of the study arms",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.",
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 500,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "105 Years",
"minimumAge": "21 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes",
"nctId": "NCT06376695",
"orgStudyIdInfo": {
"id": "RADX-P-2407",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool"
}
],
"primaryOutcomes": [
{
"measure": "Change in GI (Gastrointestinal) Health (1)"
},
{
"measure": "Change in GI (Gastrointestinal) Health (2)"
},
{
"measure": "Change in GI (Gastrointestinal) Health (3)"
},
{
"measure": "Change in GI (Gastrointestinal) Health (4)"
},
{
"measure": "Change in GI (Gastrointestinal) Health (5)"
},
{
"measure": "Change in GI (Gastrointestinal) Health (6)"
}
],
"secondaryOutcomes": [
{
"measure": "Change in feelings of anxiety"
},
{
"measure": "Change in GI-related Quality of Life (QOL)"
},
{
"measure": "Change in mood (emotional distress-depression)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (1)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (2)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (3)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (4)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (5)"
},
{
"measure": "Minimal clinically important difference (MCID) in GI Health (6)"
},
{
"measure": "Minimal clinically important difference (MCID) in feelings of anxiety"
},
{
"measure": "Minimal clinically important difference (MCID) in GI-related QOL"
},
{
"measure": "Minimal clinically important difference (MCID) in mood (emotional distress-depression)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Radicle Science"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "CT-guided bone percutaneous procedure"
}
]
},
"conditionsModule": {
"conditions": [
"Bone Metastases",
"Fractures, Bone",
"Bone Tumor"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "The Epione device is an image-guided robotized device that assists the physician during CT-guided procedures.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 33,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "EPIBONE",
"briefTitle": "EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy",
"nctId": "NCT06376682",
"orgStudyIdInfo": {
"id": "CA-BO-CIP-0060",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Successful instrument insertion with the EPIONE device."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Quantum Surgical"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-02-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Proton Stereotactic Body Radiation therapy (SBRT)"
}
]
},
"conditionsModule": {
"conditions": [
"Renal Cell Carcinoma"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "SPARE",
"briefTitle": "Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma",
"nctId": "NCT06376669",
"orgStudyIdInfo": {
"id": "J2421",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "JHM IRB",
"id": "IRB00427823",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels"
},
{
"measure": "Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values"
}
],
"secondaryOutcomes": [
{
"measure": "Number of PROTON-BASED SBRT treatment Adverse Events"
},
{
"measure": "Local progression of disease after PROTON-BASED SBRT treatment as assessed by size or appearance of lesions"
},
{
"measure": "Systemic progression of disease after PROTON-BASED SBRT treatment as assessed by appearance of lesions"
},
{
"measure": "Time to locoregional progression"
},
{
"measure": "Overall survival"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Cognitive stimulation"
},
{
"name": "Physical activity"
}
]
},
"conditionsModule": {
"conditions": [
"Aging",
"Elderly",
"Cognitive Decline",
"Physical Decline",
"Intervention Study"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Petaling Jaya",
"contacts": [
{
"email": "[email protected]",
"name": "Michael J Jenkins, PhD",
"phone": "+60374918622",
"phoneExt": "7183",
"role": "CONTACT"
}
],
"country": "Malaysia",
"facility": "Sunway University",
"geoPoint": {
"lat": 3.10726,
"lon": 101.60671
},
"state": "Selangor",
"status": "RECRUITING",
"zip": "47500"
}
]
},
"descriptionModule": {
"briefSummary": "Recent studies have shown promising cognitive and physical interventions aimed at slowing down ageing-related declines in quality of life, but they lack strong ecological validity (brief durations, unrealistic goals, no real-world application) and has yet to show robust evidence that such interventions are stable and suitable in the long-term. The investigators aim to examine whether these interventions can, over four years, significantly slow down the normal rate of ageing-related decline."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "A cohort of older Malaysian adults will be recruited and assigned to one of the groups, either cognitive stimulation, physical activity, combined cognitive stimulation and physical activity, or non-intervention control.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 400,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "60 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "MyAgeWell",
"briefTitle": "Successful Aging and Age-related Decline",
"nctId": "NCT06376656",
"orgStudyIdInfo": {
"id": "LRGS/1/2019/SYUC/02/1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Changes in cognitive scores"
},
{
"measure": "Changes in electroencephalogram (EEG)"
},
{
"measure": "Changes in structural magnetic resonance imaging (MRI)"
},
{
"measure": "Cost-benefit analysis of intervention"
},
{
"measure": "Changes in levels of human salivary lactoferrin"
},
{
"measure": "Changes in levels of human salivary C-reactive proteins"
},
{
"measure": "Changes in salivary telomere length"
}
],
"secondaryOutcomes": [
{
"measure": "Changes in depression scores"
},
{
"measure": "Changes in anxiety scores"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Sunway University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-05"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-05-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Augmented reality supportive tool"
},
{
"name": "Conventional method (AHA pocket reference card)"
}
]
},
"conditionsModule": {
"conditions": [
"Cardiopulmonary Arrest",
"Resuscitation",
"Pediatric"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Calgary",
"contacts": [
{
"email": "[email protected]",
"name": "Adam Cheng, Prof",
"phone": "403 955 2633",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Jennifer Davidson, RN BSc",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Kangsoo Kim, Ass Prof",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Yiqun Lin, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Canada",
"facility": "Alberta Children's Hospital",
"geoPoint": {
"lat": 51.05011,
"lon": -114.08529
},
"state": "Alberta",
"status": null,
"zip": "AB T3B 6A8,"
},
{
"city": "Geneva",
"contacts": [
{
"email": "[email protected]",
"name": "Johan N Siebert, MD, PD",
"phone": "795534072",
"phoneExt": "+41",
"role": "CONTACT"
},
{
"email": null,
"name": "Delphine Courvoisier, Prof",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Frederic Ehrler, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Switzerland",
"facility": "Geneva Children's Hospital, Geneva University Hospitals",
"geoPoint": {
"lat": 46.20222,
"lon": 6.14569
},
"state": null,
"status": null,
"zip": "1205"
}
]
},
"descriptionModule": {
"briefSummary": "A prospective, multicenter, randomized clinical trial in two tertiary pediatric emergency department. It will assess, amongst pediatric healthcare teams, whether the use of augmented reality supportive devices improves adherence to American Heart Association (AHA) advanced life support guidelines and performance, while reducing medication errors, when compared to groups using the AHA pocket reference card (control) during standardized, simulation-based, pediatric in-hospital cardiac arrest (IHCA) scenarios. Seventy participants will be randomized. The primary endpoint is the time to first dose of epinephrine."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Open-label, prospective, multicenter, cluster randomized controlled clinical trial",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "It will not be possible to blind study participants to study arm allocation due to the nature of the intervention(s), but they will be blinded to study objectives. The statistician will be blinded regarding the allocation of participants to the study arms for results analysis.",
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 70,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Augmented Reality to Support Cardiopulmonary Resuscitation",
"nctId": "NCT06376643",
"orgStudyIdInfo": {
"id": "InterFACE-AR",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Time to first dose of epinephrine"
}
],
"secondaryOutcomes": [
{
"measure": "Time to initiation of cardiopulmonary resuscitation"
},
{
"measure": "Time to defibrillation"
},
{
"measure": "Time to delivery of epinephrine"
},
{
"measure": "Time to delivery of amiodarone"
},
{
"measure": "Time to secure definitive airway"
},
{
"measure": "Medication dosage errors"
},
{
"measure": "Types of Medication Errors"
},
{
"measure": "Frequency of Medication Errors"
},
{
"measure": "Frequency of pauses in cardiopulmonary resuscitation"
},
{
"measure": "Duration of pauses in cardiopulmonary resuscitation"
},
{
"measure": "Causes of pauses in cardiopulmonary resuscitation"
},
{
"measure": "Cardiopulmonary resuscitation quality: Percentage of overall excellent cardiopulmonary resuscitation"
},
{
"measure": "Cardiopulmonary resuscitation quality: Chest compression fraction"
},
{
"measure": "Cardiopulmonary resuscitation quality: Peri-shock pause duration"
},
{
"measure": "Provider workload (NASA-TLX)"
},
{
"measure": "User Experience Questionnaire (UEQ)"
},
{
"measure": "System Usability Scale (SUS)"
},
{
"measure": "Unified Theory of Acceptance and Use of Technology questionnaire (UTAUT)"
},
{
"measure": "State-Trait Anxiety Inventory (STAI) form Y-1"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Geneva Children's Hospital, Geneva, Switzerland"
},
{
"name": "Alberta Children's Hospital, Calgary, Canada"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Johan Siebert, MD"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-10-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-11-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Esmolol Hcl 10Mg/Ml Inj"
}
]
},
"conditionsModule": {
"conditions": [
"Myocardial Infarction",
"Coronary Stenosis",
"Coronary Microvascular Dysfunction"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Moscow",
"contacts": [
{
"email": null,
"name": "Andrey Komarov, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Tatiana Sukhinina, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Mariy Terenicheva, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Olga Stukalova, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Sergey Ternovoy, Academic",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Goar Arutiunian, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Evgeniy Merkulov, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Viktor Shitov, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Marina Saidova, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Aleksey Ansheles, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Vladimir Sergienko, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Russian Federation",
"facility": "NMRCCardiologyRu",
"geoPoint": {
"lat": 55.75222,
"lon": 37.61556
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Study rationale: to evaluate clinical and prognostic relevance of microvascular dysfunction, coronary flow reserve and cardioprotective effects of iv administration of esmolol in patients with myocardial infarction.\n\nFirst substudy is an open randomized trial evaluating the efficacy and safety of early intravenous administration of esmolol in patients with acute ST-segment elevation myocardial infarction (MI) and relative contraindications to administration of other intravenous β1-adrenergic blocker (metoprolol etс.). Сomparison group will include patients who have not received intravenous β1-adrenergic blocker. Secondary outcome in this substudy is the degree of microvascular obstruction and infarct size according to MRI with gadolinium delayed enhancement.\n\nSecond substudy examines the quantitative parameters of coronary physiology in patients with MI and multivessel disease. Changes of coronary physiology measurements over time ((iFR, Pd/Pa, FFR, delta FFR, gradient FFR per time unit (dFFR(t)/dt), pullback pressure gradient (PPG)) measured in the infarct-related artery and in non-infarct-related arteries with diameter stenosis of 50-85% immediately after the completion of a primary percutaneous coronary intervention and during a second hospitalization (30-45 days after STEMI) will be evaluated. The comparison changes of coronary physiology over time with presence of an MVO and infarct size determined by MRI. The model of calculating coronary flow reserve (CFR) based on tridimensional reconstruction of coronary arteries and coronary physiology parameters as measured during coronary angiography will be developed. The influence of coronary physiology parameters measured after complete myocardial revascularization by PCI, and derived CFR in patients with MI on long-term clinical outcomes will be evaluated, based on prospective data collection.\n\nPrimary composite outcome in all substudies will be the sum of adverse cardiac outcomes (congestive heart failure, episodes of recurrent congestive heart failure worsening resulting in hospitalizations, cardiac mortality, MI recurrences, unstable angina, urgent myocardial revascularization) within \\> 12 months post-infarction.\n\nSecondary composite outcome in all substudies is the degree of microvascular obstruction and infarct size evaluated by MRI with gadolinium delayed enhancement."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "300 pts with MI are to be enrolled. Among them 100 pts with STEMI will be included into the substudy evaluating cardioprotective effects of early iv administration of esmolol. They will be randomized 1:1 by in arms receiving esmolol or no IV beta-blockers. In the esmolol arm the infusion will begin immediately on admission. 200 pts with MI and multivessel disease with non-IRA lesions of 50-85% diameter stenosis will be included into another substudy investigating coronary physiology. All patients will undergo PCI with IRA stenting. 50 stable patients will undergo invasive measurements of coronary physiology. Those will also undergo cardiac MRI. Other 150 pts will not undergo invasive measurements of coronary physiology during initial hospitalization. Pts in both groups will be hospitalized again in 30-40 days after MI. They will undergo stress SPECT or stress echocardiography. All patients will undergo a follow-up coronary angiography with invasive measurement of coronary physiology.",
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": "envelopes",
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 300,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ESMO-VASCMI",
"briefTitle": "Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI",
"nctId": "NCT06376630",
"orgStudyIdInfo": {
"id": "298-2024",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Composite of adverse cardiac outcomes"
}
],
"secondaryOutcomes": [
{
"measure": "Degree of microvascular obstruction"
},
{
"measure": "Infarct size"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "National Medical Research Center for Cardiology, Ministry of Health of Russian Federation"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-01-29"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-01-29"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-29"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "fibroptic bronchoscopy"
}
]
},
"conditionsModule": {
"conditions": [
"Bronchial Asthma"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "This study is to assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma"
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Pattern Of Isolated Fungi From Bronchoalveolar Lavage Among Patients With Bronchial Asthma",
"nctId": "NCT06376617",
"orgStudyIdInfo": {
"id": "MS.24.03.2743",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "assess the pattern of isolated fungi from the respiratory air way (bronchial tree) from bronchoalvealar lavage (BAL) in asthmatic patients with uncontrolled or difficult to treat asthma"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Mansoura University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05-20"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-20"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Fasting Mimicking Diet"
},
{
"name": "Chemotherapy"
}
]
},
"conditionsModule": {
"conditions": [
"Cancer, Ovarian",
"Chemotherapy Effect",
"Calorie Deficiency",
"Fasting, Intermittent"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Knoxville",
"contacts": [
{
"email": "[email protected]",
"name": "Jonathan D Boone, MD",
"phone": "865-305-5622",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "The University of Tennessee Medical Center",
"geoPoint": {
"lat": 35.96064,
"lon": -83.92074
},
"state": "Tennessee",
"status": "RECRUITING",
"zip": "37920"
}
]
},
"descriptionModule": {
"briefSummary": "This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "Outcomes Assessor",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "35 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies",
"nctId": "NCT06376604",
"orgStudyIdInfo": {
"id": "LNT55",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Quality of life by National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index (NFOSI-18) questionnaire"
},
{
"measure": "Rate of Adherence"
}
],
"secondaryOutcomes": [
{
"measure": "Change in Body Weight"
},
{
"measure": "Change in Body Composition"
},
{
"measure": "Change in HbA1c"
},
{
"measure": "Change in Insulin Like Growth Factor 1 (IGF-1) Concentration"
},
{
"measure": "Change in Fasting Insulin Concentration"
},
{
"measure": "Change in Fasting Glucose Concentration"
},
{
"measure": "Change in High-sensitivity C reactive protein Concentration"
},
{
"measure": "Change in Leptin Concentration"
},
{
"measure": "Change in planned chemotherapy regimen"
},
{
"measure": "Number of Hospitalization Days"
},
{
"measure": "Rate of Chemotherapy Side Effects"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Tennessee Medical Center"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "L-Nutra Inc"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-09-08"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Oral Vitamin B12 supplement"
},
{
"name": "Control group"
}
]
},
"conditionsModule": {
"conditions": [
"Vitamin B 12 Deficiency"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Jamshoro",
"contacts": [
{
"email": "[email protected]",
"name": "Dr. Ikram Ujjan, MBBS, PhD",
"phone": "03000506955",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Pakistan",
"facility": "Liaquat University of Medical and Health Sciences",
"geoPoint": {
"lat": 25.43773,
"lon": 68.28522
},
"state": null,
"status": null,
"zip": "76090"
}
]
},
"descriptionModule": {
"briefSummary": "Vitamin B12, a vital nutrient, plays a crucial role in red blood cell formation, neurological function, and DNA synthesis. Deficiency in B12 can lead to anemia, neurological symptoms such as tingling or numbness, and cognitive impairment. Oral B12 supplementation serves as an effective strategy to address B12 deficiency, especially for individuals with limited dietary intake or absorption issues. Regular B12 supplementation can help restore body B12 levels, alleviate deficiency-related symptoms, and support overall health and well-being."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "45 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Assessing the Efficacy of Different Carrier Systems in Oral Vitamin B12 Supplementation in Healthy Adults With B12 Deficiency",
"nctId": "NCT06376591",
"orgStudyIdInfo": {
"id": "LUMHS/B12/Temp/12.04.2024",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Supplementation effect on circulatory vitamin B12 levels"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)"
},
{
"measure": "Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)"
},
{
"measure": "Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Liaquat University of Medical & Health Sciences"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-22"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Exercise intervention"
},
{
"name": "Polar A380 wristwatch physical activity tracker"
}
]
},
"conditionsModule": {
"conditions": [
"Breast Cancer Female"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bath",
"contacts": null,
"country": "United Kingdom",
"facility": "University of Bath",
"geoPoint": {
"lat": 51.3751,
"lon": -2.36172
},
"state": null,
"status": null,
"zip": "BA2 7AY"
}
]
},
"descriptionModule": {
"briefSummary": "Supervised, prescribed exercise has positive effects on body composition, physical functioning, psychological wellbeing and quality of life for patients after breast cancer treatment. However, exercise interventions are often time consuming, commonly take place at a health or fitness facility, and usually require a trained professional to be present. Cost-effective, enjoyable and practical approaches, that can be adopted at home or in local surroundings are needed. For example, an alternative approach is using an electronic physical activity tracking wristwatch to help patients engage with exercise or physical activity. Research demonstrates the importance of structured and supervised exercise for breast cancer survivors. However, it is not known whether other approaches (e.g. home-based exercise and physical activity) alongside the use of personalised technology-enabled feedback, can cause similar improvements to health when compared to structured exercise. The overall aim of this study is to determine whether cardiorespiratory fitness is changed by a technology enabled, remotely delivered exercise intervention and to determine whether this change is similar to the change caused by a partly supervised, prescribed exercise intervention. This study will also determine the influence of both interventions on physical functioning, body composition and blood pressure."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 30,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "69 Years",
"minimumAge": "35 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Exercise Interventions for Improving Health in Breast Cancer Survivors",
"nctId": "NCT06376578",
"orgStudyIdInfo": {
"id": "245256",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Change in physical functioning"
},
{
"measure": "Change in Psychological measures"
},
{
"measure": "Change in immune profiles and function"
}
],
"primaryOutcomes": [
{
"measure": "Change in VO2max (maximum oxygen uptake)"
}
],
"secondaryOutcomes": [
{
"measure": "Change in Body composition"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Bath"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2020-01-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2020-01-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2018-09-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Best Practice"
},
{
"name": "Communication Intervention"
},
{
"name": "Communication Intervention"
},
{
"name": "Communication Intervention"
},
{
"name": "Interview"
},
{
"name": "Interview"
}
]
},
"conditionsModule": {
"conditions": [
"Colorectal Carcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Los Angeles",
"contacts": [
{
"email": "[email protected]",
"name": "Folasade P. May",
"phone": "617-620-7806",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Folasade P. May",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "UCLA / Jonsson Comprehensive Cancer Center",
"geoPoint": {
"lat": 34.05223,
"lon": -118.24368
},
"state": "California",
"status": null,
"zip": "90095"
}
]
},
"descriptionModule": {
"briefSummary": "This clinical trial tests a multilevel intervention at the clinic, provider and patient levels, to improve colonoscopy surveillance in patients with high risk colon polyps. Colorectal cancer (CRC) is a common and deadly disease that is largely preventable through the detection and removal of colorectal polyps. One million Americans are diagnosed with high risk polyps of the colon or rectum annually and are at increased risk for CRC; however, uptake of recommended repeat colonoscopy in 3 years to reduce CRC risk is low in this group. This multilevel intervention may work to improve timely colonoscopy screening for patients with high risk colon polyps."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1680,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps",
"nctId": "NCT06376565",
"orgStudyIdInfo": {
"id": "22-000647",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "CTRP (Clinical Trial Reporting Program)",
"id": "NCI-2024-02090",
"link": null,
"type": "REGISTRY"
},
{
"domain": null,
"id": "R01CA271034",
"link": "https://reporter.nih.gov/quickSearch/R01CA271034",
"type": "NIH"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Stakeholder perspectives on the multilevel intervention (Aim 1)"
},
{
"measure": "Completion of surveillance colonoscopy (Aim 2)"
},
{
"measure": "Implementation quality (Aim 3a)"
},
{
"measure": "Cost effectiveness (Aim 3b)"
}
],
"secondaryOutcomes": [
{
"measure": "Time from high risk neoplasia (HRN) diagnosis to colonoscopy (Aim 2)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "National Cancer Institute (NCI)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Jonsson Comprehensive Cancer Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-03"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-24"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-03-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"Brugada Syndrome"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milan",
"contacts": null,
"country": "Italy",
"facility": "IRCCS San Raffaele",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": null,
"zip": "20132"
},
{
"city": "Milan",
"contacts": null,
"country": "Italy",
"facility": "Milano-Bicocca University",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Brugada Syndrome (BS) is an inherited heart condition that can cause sudden cardiac arrest in young individuals. It's diagnosed through specific changes seen on an electrocardiogram (ECG). Currently, the only treatment option is a cardioverter defibrillator (ICD). Despite advances, much about BS remains unclear, including its genetic basis. This study aims to use advanced genetic sequencing and artificial intelligence to uncover new genetic factors contributing to BS. By understanding these factors better, we hope to improve risk assessment and treatment for affected individuals."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 200,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "AI4Cardio",
"briefTitle": "Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome",
"nctId": "NCT06376552",
"orgStudyIdInfo": {
"id": "AI4Cardio",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "New candidate genes, likely associated with Brugada Syndrome using an AI based approach."
}
],
"secondaryOutcomes": [
{
"measure": "Identification of genetic risk factors associated with the worse phenotype."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "IRCCS San Raffaele"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-06-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-06-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2018-12-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Bone Neoplasm",
"Rehabilitation"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The aim of the present study is to describe the course of functional recovery of patients with musculoskeletal tumours and undergone resection and reconstruction operations of lower limbs in the first six months post-surgery, differentiating them on the basis of the anatomical level involved."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "12 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "FISIO-ONCO",
"briefTitle": "Functional Recovery of Patients Undergoing Resection and Reconstruction of the Lower Limbs for Bone Tumor.",
"nctId": "NCT06376539",
"orgStudyIdInfo": {
"id": "CEAVEC: 111/2024/Oss/IOR",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Toronto Extremity Salvage Score (TESS)"
},
{
"measure": "Toronto Extremity Salvage Score (TESS)"
}
],
"secondaryOutcomes": [
{
"measure": "Range of motion (ROM)"
},
{
"measure": "Rang of motion - 2 (ROM)"
},
{
"measure": "Number of participants able to walk"
},
{
"measure": "Time Up and Go -2 (TUG)"
},
{
"measure": "Time Up and Go (TUG)"
},
{
"measure": "Muscle Strength"
},
{
"measure": "Muscle Strength-2"
},
{
"measure": "Number of day from surgery to first walking"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Istituto Ortopedico Rizzoli"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Linvoseltamab"
}
]
},
"conditionsModule": {
"conditions": [
"Multiple Myeloma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Miami",
"contacts": [
{
"email": "[email protected]",
"name": "Dickran Kazandjian, MD",
"phone": "305-243-5001",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Dickran Kazandjian, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "University of Miami",
"geoPoint": {
"lat": 25.77427,
"lon": -80.19366
},
"state": "Florida",
"status": null,
"zip": "33136"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 28,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "IMMUNOPLANT",
"briefTitle": "IMMUNOPLANT for Newly Diagnosed Multiple Myeloma",
"nctId": "NCT06376526",
"orgStudyIdInfo": {
"id": "20230236",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Minimal Residual Disease (MRD) Negativity Rate"
}
],
"secondaryOutcomes": [
{
"measure": "Sustained MRD-Negativity Rate"
},
{
"measure": "Progression-Free Survival (PFS)"
},
{
"measure": "Overall Survival"
},
{
"measure": "Number of Participants Experiencing Treatment-Related Adverse Events"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Regeneron Pharmaceuticals"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Dickran Kazandjian, MD"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2029-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Evaluation"
}
]
},
"conditionsModule": {
"conditions": [
"Penile Prosthesis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Pierre-Bénite",
"contacts": [
{
"email": "[email protected]",
"name": "Nicolas MOREL",
"phone": "+ 33 4 72 6788 37",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Clément PARAT",
"phone": "+ 33 4 72 6788 37",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "France",
"facility": "Department of Urology, Lyon Sud Hospital,",
"geoPoint": {
"lat": 45.7009,
"lon": 4.82511
},
"state": null,
"status": null,
"zip": "69310"
}
]
},
"descriptionModule": {
"briefSummary": "Erectile dysfunction is a highly prevalent pathology. When oral or injectable pharmacological treatments prove ineffective, the treatment of choice is penile prosthesis which provides the possibility of sexual activity with penetration.\n\nUnfortunately, current prostheses are difficult (or even impossible) to manipulate for some patients. Many patients underutilize their device due to difficulties in using the pump related to mechanical issues (difficult grip, lack of strength, etc.) or sensory issues (altered proprioception, etc.), resulting in an inability to achieve rigidity that allows optimal satisfaction for the patient and/or partners.\n\nThese difficulties correspond to a significant portion of dissatisfaction among patients with penile prostheses.\n\nActually, no study has evaluated patients' ability to manipulate the pump of their penile prosthesis, as well as the association between these manipulation abilities, the rigidity of erections with a penile prosthesis, and patient and partner sexual satisfaction.\n\nIn this descriptive study, the primary outcome is to describe the manipulation abilities of patients with penile prostheses during follow-up consultations after prosthesis implantation.\n\nThe secondary outcomes are to estimate the association of various markers related to penile prosthesis manipulation (overall hand grip strength, pinch grip strength, proprioception, and discrimination) with\n\n* Rigidity of erections with penile prosthesis\n* Patient's sexual satisfaction\n* Partner's sexual satisfaction\n* Satisfaction related to pump manipulation"
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "BASIC_SCIENCE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "MALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ECM3P",
"briefTitle": "Evaluation of Penile Prosthesis Pump Manipulation",
"nctId": "NCT06376513",
"orgStudyIdInfo": {
"id": "69HCL24_0031",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Describing the manipulation abilities of patients with penile prosthesis : overall hand grip strength"
},
{
"measure": "Describing the manipulation abilities of patients with penile prosthesis : pinch grip strength"
},
{
"measure": "Describing the manipulation abilities of patients with penile prosthesis : proprioception"
},
{
"measure": "Describing the manipulation abilities of patients with penile prosthesis :discrimination"
},
{
"measure": "Describing the manipulation abilities of patients with penile prosthesis :upper limb function for activities of daily living"
}
],
"secondaryOutcomes": [
{
"measure": "Correlation of manipulation parameters (main outcome) with rigidity of erections"
},
{
"measure": "Correlation of manipulation parameters (main outcome) with patient's sexual satisfaction modified EDITS"
},
{
"measure": "Correlation of manipulation parameters (main outcome) with patient's sexual satisfaction QoLSPP"
},
{
"measure": "Correlation of manipulation parameters (main outcome) with partner's sexual satisfaction"
},
{
"measure": "Correlation of manipulation parameters (main outcome) with satisfaction related to pump manipulation (self-made questionnaire)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hospices Civils de Lyon"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "tDCS with cognitive training programme"
}
]
},
"conditionsModule": {
"conditions": [
"Transcranial Direct Current Stimulation",
"Post-Concussion Syndrome",
"Functional Magnetic Resonance Imaging",
"Magnetic Resonance Spectroscopy"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Hung Hom",
"contacts": null,
"country": "Hong Kong",
"facility": "The Hong Kong Polytechnic University",
"geoPoint": {
"lat": 22.30715,
"lon": 114.18532
},
"state": "Kowloon",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Globally, 10 million new traumatic brain injury (TBI) cases are estimated annually, with mild traumatic brain injury (mTBI) accounting for 75-90% of all TBI cases. It is estimated that 40-80% of individuals with mTBI may experience the post-concussion syndrome (PCS), which is characterized by a range of physical, cognitive, and emotional symptoms. Although the underlying basis of cognitive dysfunction of patients with persistent PCS remains to be clarified, converging evidence shows that the clinical symptoms is underpinned by abnormal neural information processing as a result of axonal injury due to mTBI. Recent studies have demonstrated abnormalities in both structural and functional cortical connectivity, and a loss of cortical excitability-inhibitory (E/I) balance after TBI. Yet, there is no consensus for treating chronic symptoms of concussion, and PCS remains a chronic and highly disabling condition. One potential treatment option is transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique that has been shown to modify behavior by enhancing connectivity between targeted brain areas. However, research on the therapeutic effect of tDCS on PCS symptoms is limited, and the neurologic mechanisms underlying its effects are not well understood. The proposed study aims to address these knowledge gaps by examining the effects of tDCS on the central nervous system function in patients with PCS, with a specific focus on functional cortical connectivity and cognitive functions such as processing speed and executive function. The study also aims to add value to existing evidence by potentially opening new directions for designing intervention programs for the treatment of PCS after mTBI."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effects of tDCS for Enhancing Cognitive Function in Individuals With Persistent Post-Concussion Syndrome",
"nctId": "NCT06376500",
"orgStudyIdInfo": {
"id": "HSEARS20240223001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Exploratory mediator - default mode network (DMN) activation"
},
{
"measure": "Exploratory mediator - excitability-inhibitory (E/I) ratio"
}
],
"primaryOutcomes": [
{
"measure": "Executive function"
}
],
"secondaryOutcomes": [
{
"measure": "Change in CANTAB® cognitive test - Reaction Time (RTI)"
},
{
"measure": "Change in CANTAB® cognitive test - Multitasking Test (MTT)"
},
{
"measure": "Change in CANTAB® cognitive test - Spatial Working Memory (SWM)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "The Hong Kong Polytechnic University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Flow rate evaluation"
}
]
},
"conditionsModule": {
"conditions": [
"Bronchiolitis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "São Paulo",
"contacts": [
{
"email": "[email protected]",
"name": "Milena S Nascimento",
"phone": "55 11 984520061",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Brazil",
"facility": "Hospital Israelita Albert Eisntein",
"geoPoint": {
"lat": -23.5475,
"lon": -46.63611
},
"state": null,
"status": "RECRUITING",
"zip": "05653000"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this prospective clinical study is to evaluate the effect of different High Flow Nasal Cannula (HFNC) flow rates on diaphragm, rectoabdominal, and oblique thickening fraction, and to determine whether this effect depends on the action of HFNC flow rates on Functional Residual Capacity (FRC) in Infants under 2 years of age with a diagnosis of bronchiolitis and indication for use of HFNC. The main question\\[s\\] it aims to answer are:\n\n* If the thickening fraction of the abdominal muscle and diaphragm will change at the different flow rates evaluated\n* If the end-expiration lung impedance (EELZ) will change at the different flow rates evaluated\n\nThe belt will be installed around the chest before the start of the change in flow rates and monitoring with Electrical Impedance Tomography (EIT) will be initiated. Patients will be positioned in dorsal decubitus elevated 10 to 20 degrees and monitoring will be performed continuously during all flow rate variations and also during the ultrasound performance.\n\nFour different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.\n\nThe randomization of the order of application of the phases will be carried out in blocks, so that the homogeneity of the sequences is maintained even if the collection is interrupted before reaching the total number of individuals. The blocks will be of size two and four and the test and production lists will be generated with the help of the R packages."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "A prospective clinical study to evaluated four different flow rate in infants with bronchiolitis using high flow nasal cannula",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "Patient will not know the flow rate sequence used during the assessment",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 82,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "24 Months",
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Pulmonary Aeration and Muscle Thickening Fraction: Association of Electrical Impedance Tomography and Ultrasound",
"nctId": "NCT06376487",
"orgStudyIdInfo": {
"id": "75202423.2.0000.0071",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "diaphragm thickening fraction"
},
{
"measure": "abdominal muscle thickening fraction"
},
{
"measure": "EELZ (end-expiration lung impedance)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Fundação de Amparo à Pesquisa do Estado de São Paulo"
},
{
"name": "Feculdade de Medicina da Universidade de Sao Paulo - Brasil"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Israelita Albert Einstein"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Hemay005"
}
]
},
"conditionsModule": {
"conditions": [
"Psoriasis"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 24,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage",
"nctId": "NCT06376474",
"orgStudyIdInfo": {
"id": "HM005PS1S06",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax）"
},
{
"measure": "Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t）"
},
{
"measure": "Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf)"
},
{
"measure": "Relevant pharmacokinetic parameters，half-life (T1/2)"
},
{
"measure": "Relevant pharmacokinetic parameters，clearance (CL/F)"
},
{
"measure": "Relevant pharmacokinetic parameters，volume of distribution (Vz/F)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Ganzhou Hemay Pharmaceutical Co., Ltd"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Data collection"
}
]
},
"conditionsModule": {
"conditions": [
"Gastrointestinal Dysfunction"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Stoke-on-Trent",
"contacts": null,
"country": "United Kingdom",
"facility": "University Hospitals of North Midlands NHS Trust",
"geoPoint": {
"lat": 53.00415,
"lon": -2.18538
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Part A Multiple organ dysfunction syndrome is one of the main problems in critically ill patients. Several organ dysfunctions are routinely and systematically monitored in patients admitted to intensive care units. Gastrointestinal dysfunction is currently not included in multiple organ dysfunction scores and lacks a standardised approach. At the same time, investigators earlier studies have shown that gastrointestinal dysfunction plays an essential role in the course of illness in intensive care patients. A tool for measuring dysfunction is needed to enable future studies on interventions to improve gastrointestinal function. The GIDS (GastroIntestinal Dysfunction Score) combines different clinical signs and symptoms commonly observed and documented in patients in the ICU into a scoring system, allowing distinguishing between different grades of severity of dysfunction. The investigators will only use observations documented during the patient's stay in the intensive care unit without additional measurements and calculate gastrointestinal (GIDS) and other organ dysfunction scores.\n\nPart B Phosphate is an electrolyte commonly measured and often corrected, while the indications and clear guidance for correction are insufficiently studied. The results of this study will assist in specifying indications for the correction of phosphate levels better and refine the management strategies in the future. Only phosphate levels measured as part of routine care will be documented, no additional samples for study purposes will be taken, and the study will not influence the treatment of phosphate disorders."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 120,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "GUTPHOS",
"briefTitle": "Prospective, Multicentre Study to Validate the GastroIntestinal Dysfunction Score (GIDS) and Describe Prevalence, Outcomes, and Management of Phosphate Disorders in Intensive Care Patients",
"nctId": "NCT06376461",
"orgStudyIdInfo": {
"id": "333874",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "28 day outcome"
},
{
"measure": "90 day outcome"
}
],
"secondaryOutcomes": [
{
"measure": "ICU length of stay"
},
{
"measure": "ICU length of stay"
},
{
"measure": "Hospital length of stay"
},
{
"measure": "Hospital length of stay"
},
{
"measure": "Free of organ support"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University Hospitals of North Midlands NHS Trust"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-07"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Chronic Cough"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cottingham",
"contacts": [
{
"email": "[email protected]",
"name": "Caroline Wright",
"phone": "01482624067",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Rachel H Thompson, Bsc",
"phone": "01482 461800",
"phoneExt": "Thompson",
"role": "CONTACT"
},
{
"email": null,
"name": "Caroline Wright, Bsc",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United Kingdom",
"facility": "Redspiratory Medicine, First Floor, Daisy Building, Castle Hill Hospital",
"geoPoint": {
"lat": 52.50243,
"lon": -0.7554
},
"state": "East Yorkshiure",
"status": "RECRUITING",
"zip": "HU16 5JQ"
}
]
},
"descriptionModule": {
"briefSummary": "Cough has previously been described by the type of cough you have ie such as wet, dry, and chesty, and also by its features such as how often you are coughing its,intensity, and severity, but never has the varying patterns of cough been studied in any detail and it could be that the pattern of the cough is closely related to patient-perceived intensity, frequency and most importantly severity. Cough is a symptom and like any other symptom (such as pain) the severity of it can only be gauged by the patient experiencing it.\n\nWe have created a one-page brand newl questionnaire that shows 4 distinct cough patterns that we believe exist and an empty field designed so that patients can record a pattern of cough they experience which is not already a choice on the questionnaire. The questionnaire also records patients' experience of how frequent, and intense, the cough is, and how it disrupts their lives, on a 1-10 scale (Visual analogue scale), the sum of these scores is collated and this gives us a severity score. The first phase of the project is to determine whether 30 Chronic cough patients understand the questionnaire, and are able to complete it with little direction, and if the cough patterns we identified encompassed all pattern types. second part of the study is to look at how repeatable the questionnaire is when completed over a 6 week period."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough",
"nctId": "NCT06376448",
"orgStudyIdInfo": {
"id": "cc-obs-01",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The primary objective of the study is to characterize and identify the different patterns of cough in chronic cough patients"
}
],
"secondaryOutcomes": [
{
"measure": "measure of cough severity"
},
{
"measure": "describe any correlation between severity of cough and cough pattern"
},
{
"measure": "reproducibility of questionnnare"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Hull University Teaching Hospitals NHS Trust"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-02-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-10-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-10-24"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Herombopag Olamine Tablets"
}
]
},
"conditionsModule": {
"conditions": [
"Cancer, Therapy-Related"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronous/sequential radioimmunoinduced thrombocytopenia in the real world.\n\nThe subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia.\n\nThis study will retrospectively and prospectively collect real-world data related to investigational drugs, and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia. The study included a screening period (no more than one week) and a treatment period (at least two cycles).Participants meeting protocol inclusion criteria were defined as having platelet values \\< 100×109/L during radioimmunotherapy."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia",
"nctId": "NCT06376435",
"orgStudyIdInfo": {
"id": "HBHQ-CTIT-RWS",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The proportion of patients recovered to 100×109/L"
}
],
"secondaryOutcomes": [
{
"measure": "The proportion of patients recovered to 75×109/L"
},
{
"measure": "Time for platelet recovery to 100×109/L"
},
{
"measure": "Proportion of patients with treatment delay or dose reduction"
},
{
"measure": "TRAE"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hebei Medical University Fourth Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Spongioflex®"
},
{
"name": "non-operated"
}
]
},
"conditionsModule": {
"conditions": [
"Meniscus Lesion"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Dortmund",
"contacts": [
{
"email": "[email protected]",
"name": "Sven Behrendt, MD",
"phone": "+49231 8626064",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Sven Behrendt, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Germany",
"facility": "Privatpraxis für Knie und Schulterchirurgie",
"geoPoint": {
"lat": 51.51494,
"lon": 7.466
},
"state": null,
"status": "RECRUITING",
"zip": "44137"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to learn if partial meniscal replacement can prevent or postpone total meniscal replacement, in adult patients (female/male) with partial meniscal loss. The main questions it aims to answer are:\n\n* Can partial meniscal replacement improve knee function?\n* Can partial meniscal replacement prevent/postpone total meniscal replacement/knee prothesis? Researchers will compare the results of the operated group with patients not willing to be operated but with partial meniscal loss to see if the operation improves knee function.\n\nParticipants will be operated and have to attend follow-up visits with MRI after 6 months up to 5 years after surgery."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "no masking, patient decides which group",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Sterile Allogeneic Spongioflex® Allograft as Partial Meniscal Replacement After Incomplete Meniscal Loss",
"nctId": "NCT06376422",
"orgStudyIdInfo": {
"id": "EU-CT-2023-508271-36-00",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "To evaluate efficacy of the procedure"
},
{
"measure": "Improvement of International Knee Documentation Committee (IKDC) score (between 0 and 100, the higher the better)"
},
{
"measure": "Improvement of Knee Injury and Osteoarthritis Outcome Score (KOOS) score (between 0 and 100, the higher the better)"
},
{
"measure": "Improvement of Visual Analogue Scale (VAS) Pain Score (between 0 and 10, the lower the better)"
}
],
"secondaryOutcomes": [
{
"measure": "Safety of the patient (adverse events (AE) and serious adverse events (SAE))"
},
{
"measure": "Efficacy of the procedure, progression to osteoarthrosis"
},
{
"measure": "Menuiscus size"
},
{
"measure": "extrusion of meniscus"
},
{
"measure": "Size of meniscal extrusion"
},
{
"measure": "Patient satisfaction"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Privatpraxis für Knie- und Schulterchirurgie"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2031-04-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Nutrafol Women's Hair Growth Supplement"
},
{
"name": "Nutrafol Women's Balance Hair Growth Supplement"
},
{
"name": "Nutrafol Women's Vegan Hair Growth Supplement"
},
{
"name": "Nutrafol Women's Postpartum Hair Growth Supplement"
}
]
},
"conditionsModule": {
"conditions": [
"Hair Thinning"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Sacramento",
"contacts": [
{
"email": null,
"name": "Nasima Afzal",
"phone": "916-750-2463",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Integrative Skin Science and Research",
"geoPoint": {
"lat": 38.58157,
"lon": -121.4944
},
"state": "California",
"status": null,
"zip": "95815"
}
]
},
"descriptionModule": {
"briefSummary": "A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Single Group Assignment 6-month, single-center, prospective interventional study",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 180,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females",
"nctId": "NCT06376409",
"orgStudyIdInfo": {
"id": "NW-HGN-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The percent change in hair growth rate at Day 180 relative to baseline (Day 0)"
}
],
"secondaryOutcomes": [
{
"measure": "The percent change in hair growth rate at Day 90 relative to baseline (Day 0)"
},
{
"measure": "The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days"
},
{
"measure": "The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days"
},
{
"measure": "The change in terminal to vellus ratio"
},
{
"measure": "The change in terminal to vellus ratio"
},
{
"measure": "The change in anagen to telogen ratio"
},
{
"measure": "The change in anagen to telogen ratio"
},
{
"measure": "The change in average number of hairs per follicular unit"
},
{
"measure": "The change in average number of hairs per follicular unit"
},
{
"measure": "The change in total hair width per cm2"
},
{
"measure": "The change in total hair width per cm2"
},
{
"measure": "The change in mean inter-follicular distance"
},
{
"measure": "The change in mean inter-follicular distance"
},
{
"measure": "Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days"
},
{
"measure": "Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Nutraceutical Wellness Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "albendazole and praziquantel"
},
{
"name": "Albendazole"
}
]
},
"conditionsModule": {
"conditions": [
"Neurocysticercosis"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 300,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "NeuroSolve",
"briefTitle": "Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis",
"nctId": "NCT06376396",
"orgStudyIdInfo": {
"id": "101103306",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Cyst resolution or reduction in both study arms"
}
],
"secondaryOutcomes": [
{
"measure": "Seizures frequency"
},
{
"measure": "Quality of Life questionnaire"
},
{
"measure": "Headache"
},
{
"measure": "Serological test results correlation with neuroimaging results"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Muhimbili University of Health and Allied Sciences"
},
{
"name": "National Institute for Medical Research, Tanzania"
},
{
"name": "Sokoine University of Agriculture"
},
{
"name": "University of Zambia"
},
{
"name": "University Ghent"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "R-Evolution Worldwide S.r.l. Impresa Sociale"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Tonsillectomy"
},
{
"name": "Tonsillotomy"
}
]
},
"conditionsModule": {
"conditions": [
"Obstructive Sleep Apnea",
"Tonsillar Hypertrophy"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The primary purpose of this randomized controlled trial s to investigate whether surgical reduction of palatine tonsils (tonsillotomy) is a superior treatment compared to complete surgical removal of palatine tonsils (tonsillectomy) in adults patients with obstructive sleep apnea and concomitant enlarged tonsils in regards of perioperative and postoperative morbidity."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 464,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Tonsillectomy vs. Tonsillotomy in Adults With Obstructive Sleep Apnea",
"nctId": "NCT06376383",
"orgStudyIdInfo": {
"id": "TETT-RHG",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "The Central Denmark Region Committees on Health Research Ethics",
"id": "110500",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Postoperative hemorrhage"
},
{
"measure": "Postoperative pain"
},
{
"measure": "Recovery time - Sick leave"
},
{
"measure": "Morbidity"
}
],
"secondaryOutcomes": [
{
"measure": "AHI"
},
{
"measure": "DISE - VOTE"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "University of Aarhus"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2025-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Application of computer-assisted cognitive rehabilitation program"
}
]
},
"conditionsModule": {
"conditions": [
"Epilepsy",
"Computer-assisted Cognitive Rehabilitation",
"Quality of Life"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Selçuklu",
"contacts": null,
"country": "Turkey",
"facility": "ülkü Saygili Düzova",
"geoPoint": {
"lat": 37.8842,
"lon": 32.49222
},
"state": "Konya",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this study is to examine the effects of the RehaCom Computer-Assisted Rehabilitation Program Applied to Epilepsy Patients on Self-Management, Cognitive Function and Quality of Life."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "60 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of a Computer-Assisted Rehabilitation Program on Epilepsy Patient",
"nctId": "NCT06376370",
"orgStudyIdInfo": {
"id": "16.04.24/2",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mini Mental State Test"
},
{
"measure": "Epilepsy Quality of Life Scale"
},
{
"measure": "MOXO Test"
},
{
"measure": "Epilepsy Self-Management Scale"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Selcuk University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2024-06-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-26"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Foot Massage with roller"
}
]
},
"conditionsModule": {
"conditions": [
"Breast Neoplasms",
"Over Cancer",
"Foot Massage"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Selçuklu",
"contacts": null,
"country": "Turkey",
"facility": "ülkü Saygili Düzova",
"geoPoint": {
"lat": 37.8842,
"lon": 32.49222
},
"state": "Konya",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "It was aimed to examine the roles in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane-based chemotherapy and the effect of foot massage on neuropathy and quality of life."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 54,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Foot Massage With Roles on Cancer Patients",
"nctId": "NCT06376357",
"orgStudyIdInfo": {
"id": "16.04.24/1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "EORTC QLQ C-30 Quality of Life Scale"
},
{
"measure": "CIPN20 Neuropathy Scale"
},
{
"measure": "One Leg Standing Test"
},
{
"measure": "Brief Pain Inventory BPI"
},
{
"measure": "Pain Threshold Assessment Test"
},
{
"measure": "Two Point Discrimination"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Selcuk University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2024-06-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-27"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "myofascial release with tennis ball"
}
]
},
"conditionsModule": {
"conditions": [
"Cancer",
"Neuropathy",
"Therapy-Associated Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Selçuklu",
"contacts": null,
"country": "Turkey",
"facility": "ülkü Saygili Düzova",
"geoPoint": {
"lat": 37.8842,
"lon": 32.49222
},
"state": "Konya",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "This research; It was aimed to evaluate the effect of myofascial release using a tennis ball on balance and quality of life in cancer patients who developed peripheral neuropathy."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "25 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "The Effect of Tennis Ball on Balance and Quality of Life in Cancer Patients With Neuropathy.",
"nctId": "NCT06376344",
"orgStudyIdInfo": {
"id": "16.04.24",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "EORTC QLQ C-30- CIPN20 Scale"
},
{
"measure": "One Leg Standing Test"
},
{
"measure": "Lateral Reach Test"
},
{
"measure": "Pain Assessment"
},
{
"measure": "Pressure Pain Threshold Assessment"
},
{
"measure": "Two Point Discrimination"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Selcuk University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-07-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2024-06-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-28"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "washed microbiota transplantation"
}
]
},
"conditionsModule": {
"conditions": [
"Attention-deficit/Hyperactivity Disorder"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nanjing",
"contacts": [
{
"email": "[email protected]",
"name": "Faming Zhang, PhD",
"phone": "086-025-58509883",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Department of Microbiota Medicine & Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": "Jiangsu",
"status": null,
"zip": null
},
{
"city": "Nanjing",
"contacts": null,
"country": "China",
"facility": "SIR RUN RUN hospital of Nanjing Medical University",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": "Jiangsu",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention and hyperactivity-impulsivity. ADHD is often accompanied by oppositional defiant disorder and sleep disturbance, and can increase the risk of other psychiatric disorders, functional impairment in academic and occupational performance. Recently, gut microbiota has been implicated in the ADHD via gut-brain axis. In this study, investigators aimed to evaluate the efficacy of WMT for core ADHD symptoms and its comorbidities using specialized questionnaires for ADHD and investigate the underlying mechanism."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 50,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "17 Years",
"minimumAge": "6 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder",
"nctId": "NCT06376331",
"orgStudyIdInfo": {
"id": "ADHD20240403",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "change of Swanson, Nolan and Pelham-IV (SNAP-IV)."
},
{
"measure": "change of Chinese version of the Conners abbreviated symptom questionnaire (C-ASQ)."
}
],
"secondaryOutcomes": [
{
"measure": "change of the Sleep Disturbance Scale for Children (SDSC)."
},
{
"measure": "change of the Gastrointestinal Symptom Rating Scale (GSRS) ."
},
{
"measure": "the difference of the gut microbe composition between children with ADHD and healthy children by sequencing faecal metagenome."
},
{
"measure": "the difference of the serum neurotransmitters between children with ADHD and healthy children"
},
{
"measure": "intestinal barrier"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "SIR RUN RUN hospital of Nanjing Medical University"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "The Second Hospital of Nanjing Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-07-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-24"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-20"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Inotrope"
},
{
"name": "Mechanical circulatory support"
},
{
"name": "anti-bodies"
}
]
},
"conditionsModule": {
"conditions": [
"Circulatory Shock",
"Sepsis",
"Cardiogenic Shock",
"Major Trauma",
"Surgical Shock"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Toronto",
"contacts": null,
"country": "Canada",
"facility": "St Michael's Hospital",
"geoPoint": {
"lat": 43.70011,
"lon": -79.4163
},
"state": "Ontario",
"status": null,
"zip": "M5B 1W8"
}
]
},
"descriptionModule": {
"briefSummary": "In-hospital mortality of patients admitted in the intensive care unit (ICU) for circulatory shock remains high (between 20 and 40%).\n\nCurrently, there are no markers that allow us to classify patients with circulatory shock at higher risk of early and late bad outcomes, or who may better respond to a specific intervention.\n\nTo understand the contribution of biological heterogeneity to circulatory shock independently from its etiology, the ShockCO-OP Research Program aims to use clustering approaches to re-analyze existing clinical and molecular data from several large European and North American prospective cohorts and clinical trials.\n\nThis will enable an improvement in risk prediction and a better patient selection in future clinical trials to assess a personalized therapy (i.e., prospective enrollment based on a biological/molecular signature)."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "OTHER"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "90 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ShockCO-OP",
"briefTitle": "Shock and Acute Conditions OutcOmes Platform",
"nctId": "NCT06376318",
"orgStudyIdInfo": {
"id": "19-138",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Mortality rate"
}
],
"secondaryOutcomes": [
{
"measure": "Mortality rate"
},
{
"measure": "Renal replacement therapy use rate"
},
{
"measure": "Mechanical circulatory support use rate"
},
{
"measure": "Vasopressors and inotropes-free days"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Helsinki"
},
{
"name": "University of Ottawa"
},
{
"name": "University of Leipzig"
},
{
"name": "University of Nancy"
},
{
"name": "McGill University"
},
{
"name": "Mayo Clinic"
},
{
"name": "University of Paris 5 - Rene Descartes"
},
{
"name": "University of Toronto"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Saint-Louis Hospital, Paris, France"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-07-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "EndoBarrier"
}
]
},
"conditionsModule": {
"conditions": [
"Type 2 Diabetes",
"Obstructive Sleep Apnoea",
"Obesity"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Birmingham",
"contacts": null,
"country": "United Kingdom",
"facility": "City Hospital",
"geoPoint": {
"lat": 52.48142,
"lon": -1.89983
},
"state": null,
"status": null,
"zip": "B18 7QH"
}
]
},
"descriptionModule": {
"briefSummary": "Obstructive sleep apnoea (OSA) is a common condition in which the upper airways (windpipe) collapse repeatedly during sleep, blocking the flow of air into the lungs. It is characterized by repetitive pauses in breathing during sleep, despite the effort to breathe, and is associated with a reduction in the amount of oxygen in the blood (oxygen saturation). People with OSA are at risk of heart disease, high blood pressure, stroke, depression, and premature death. OSA is usually treated using a continuous positive airway pressure (CPAP) machine. This involves the patient wearing a face mask during sleep which is connected to the machine which supplies a constant steam of air to help keep the airways open. This improves the symptoms and hopefully the long-term outlook, but it is an uncomfortable solution. OSA is associated with obesity and weight loss can improve or even cure it. Treatment with EndoBarrier (placement of a thin flexible tube that is placed inside your intestine creating a physical barrier between the intestinal wall and the food so less can be absorbed) can be associated with significant weight loss and can improve blood sugar control in patients with type 2 diabetes related to their weight (diabesity). This study aims to find out if EndoBarrier treatment can improve OSA in patients with diabesity to the extent that some patients no longer require their CPAP machine treatment."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 12,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "End-OSA",
"briefTitle": "EndoBarrier in Obstructive Sleep Apnoea Study",
"nctId": "NCT06376305",
"orgStudyIdInfo": {
"id": "176786",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Requirement for continuous positive airway pressure (CPAP) treatment will be assessed by sleep studies at screening and then every 3 months, up to 24 months"
}
],
"secondaryOutcomes": [
{
"measure": "Apnea-hypopnea index (AHI) is measured by sleep studies at screening and then every 3 months, up to 24 months"
},
{
"measure": "Obstructive sleep apnoea (OSA) symptoms are measured by sleep studies at screening, and then every 3 months, up to 24 months"
},
{
"measure": "Continuous positive airway pressure (CPAP) pressures are measured by sleep studies at screening, and then every 3 months, up to 24 months"
},
{
"measure": "Glycated haemoglobin measured by blood test (HbA1c) at screening, baseline, and then every 3 months, up to 24 months"
},
{
"measure": "Fasting plasma glucose is measured by blood test(fasting plasma glucose) at baseline, and then at 12 and 24 months"
},
{
"measure": "Weight and Body mass index (BMI) is measured by checking weight in kilograms as well as height (in metres) ( weight and height will be combined to report BMI in kg/m^2) at screening, baseline, and then every 3 months, up to 24 months"
},
{
"measure": "Composite scores of NAFLD severity derived from the blood measurements of Alanine Aminotransferase in U/L, Aspartate Aminotransferase in U/L, platelets in x10^9/L and serum albumin in g/L as well as age in years and BMI"
},
{
"measure": "Circulating free testosterone, fasting insulin and C-Peptide are measured by blood tests at baseline, and then at 3, 12 and 24 months"
},
{
"measure": "Blood pressure is measured by checking blood pressure at sitting at screening, baseline, and then every 3 months, up to 24 months"
},
{
"measure": "Diabetes treatment including need for insulin is measured at baseline, and then every 3 months, up to 24 months21 and 24 months"
},
{
"measure": "Quality of life scores is measured by EQ-5D questionnaire at baseline and then at 6, 12 and 24 months"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Association of British Clinical Diabetologists"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Dr Bob Ryder"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2019-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2019-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2016-03"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
{
"largeDocumentModule": {
"largeDocs": [
{
"date": "2024-03-12",
"filename": "Prot_000.pdf",
"hasIcf": false,
"hasProtocol": true,
"hasSap": false,
"label": "Study Protocol",
"size": 320618,
"typeAbbrev": "Prot",
"uploadDate": "2024-03-13T09:04"
},
{
"date": "2024-03-12",
"filename": "ICF_001.pdf",
"hasIcf": true,
"hasProtocol": false,
"hasSap": false,
"label": "Informed Consent Form",
"size": 156721,
"typeAbbrev": "ICF",
"uploadDate": "2024-03-13T09:05"
}
]
}
}
| false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases"
}
]
},
"conditionsModule": {
"conditions": [
"Solid Tumor Leptomeningeal Metastasis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Hangzhou",
"contacts": [
{
"email": "[email protected]",
"name": "Ting Zhang, Prof.",
"phone": "+8615157125533",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "The Second Affiliated Hospital of Zhejiang University",
"geoPoint": {
"lat": 30.29365,
"lon": 120.16142
},
"state": "Zhejiang",
"status": "RECRUITING",
"zip": "310000"
}
]
},
"descriptionModule": {
"briefSummary": "The goal of this prospective, single-arm exploratory clinical study is to explore the safty and efficacy of whole-brain radiotherapy combined with Thiotepa sheath injection combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors\n\nHow works well was the combined therapy？ How safe was combined therapy？ Participants will receive whole brain radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks. Evaluate the efficacy and safety every 2 cycles.\n\nResearchers will evaluate whether this combination treatment is safe and whether it is more effective than previous studies."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": "Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Prospective Study of Whole-Brain RT Combined With Thiotepa Sheath Injection Combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors",
"nctId": "NCT06376292",
"orgStudyIdInfo": {
"id": "Y⒛24-0106",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]"
}
],
"secondaryOutcomes": [
{
"measure": "OS"
},
{
"measure": "3-month PFS"
},
{
"measure": "6-month PFS"
},
{
"measure": "1-year PFS"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Second Affiliated Hospital, School of Medicine, Zhejiang University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-02-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-02-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-02-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "IEM-EP"
}
]
},
"conditionsModule": {
"conditions": [
"Metabolic Disease",
"Mitochondrial Diseases",
"Epilepsy in Children",
"Epilepsy",
"LHON",
"Motor Neuron Disease"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Inborn Errors of metabolism comprise a large number of rare conditions with a collective incidence of around 1/2000 newborns. Many disorders are treatable provided that a correct diagnosis can be established in time, and for many diseases novel therapies are being developed. Without treatment, many of the conditions result in early death or severe irreversible handicaps.\n\nThe Centre for Inherited Metabolic Diseases, CMMS at Karolinska university hospital, is an integrated expert center where clinical specialists work closely together with experts in laboratory medicine, combining clinical genetics, clinical chemistry, pediatrics, neurology, and endocrinology. The center serves the whole Swedish population with diagnostics and expert advice on IEM and has a broad arsenal of biochemical investigations designed to detect defects in intermediary metabolism."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Genetic Diagnosis in Inborn Errors of Metabolism",
"nctId": "NCT06376279",
"orgStudyIdInfo": {
"id": "2008/351-31",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Genetic variant identification using NGS for diagnosis"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Karolinska Institutet"
}
],
"leadSponsor": {
"class": "OTHER_GOV",
"name": "Region Stockholm"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "ENROLLING_BY_INVITATION",
"primaryCompletionDateStruct": {
"date": "2030-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2008-04-29"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "nutritional supplements"
}
]
},
"conditionsModule": {
"conditions": [
"Sarcopenia"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Taipei",
"contacts": [
{
"email": "[email protected]",
"name": "Ding-cheng Chan, DR",
"phone": "+886-2-23123456",
"phoneExt": "67095",
"role": "CONTACT"
}
],
"country": "Taiwan",
"facility": "Department of Geriatrics and Gerontology, National Taiwan University Hospital",
"geoPoint": {
"lat": 25.04776,
"lon": 121.53185
},
"state": null,
"status": "RECRUITING",
"zip": "100"
}
]
},
"descriptionModule": {
"briefSummary": "Taiwan entered an aging society in 2018 and is expected to transition into a super-aged society by 2025. With the increasing elderly population, age-related diseases pose urgent challenges to modern society. According to the Ministry of Health and Welfare's National Health Statistics in 2018, the prevalence of sarcopenia in Taiwan among individuals aged 65 and older is 23.6% for males and 18.6% for females. Sarcopenia, characterized by the loss of skeletal muscle mass due to aging, coupled with decreased muscle strength and/or reduced physical performance, poses a significant risk for disability, decreased quality of life, and increased mortality.\n\nExisting research indicates that appropriate nutrition and exercise can slow the onset of sarcopenia and even increase muscle mass to reverse its effects. This study is an interventional clinical trial recruiting middle-aged and elderly patients with sarcopenia or pre-sarcopenia. The intervention involves a combination of branched-chain amino acids and medium-chain triglyceride products, and the study aims to assess the effectiveness of this intervention for sarcopenia in middle-aged and elderly individuals."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 80,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals",
"nctId": "NCT06376266",
"orgStudyIdInfo": {
"id": "202305083RSC",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "the scale of sarcopenia"
},
{
"measure": "the scale of sarcopenia"
},
{
"measure": "the scale of sarcopenia"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "National Taiwan University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2023-12-29"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-10-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "[68Ga]Ga-EVS459"
},
{
"name": "[177Lu]Lu-EVS459"
}
]
},
"conditionsModule": {
"conditions": [
"Ovarian Cancer",
"Lung Cancer"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[177Lu\\]Lu-EVS459 and the safety and imaging properties of \\[68Ga\\]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (non-sq. NSCLC)."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 96,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers",
"nctId": "NCT06376253",
"orgStudyIdInfo": {
"id": "CGIZ943A12101",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "CTIS",
"id": "2023-507674-41-00",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of participants with dose limiting toxicities of [177Lu]Lu-EVS459"
},
{
"measure": "Incidence and severity of adverse events and serious adverse events of [177Lu]Lu- EVS459"
},
{
"measure": "Dose modifications for [177Lu]Lu- EVS459"
},
{
"measure": "Dose intensity for [177Lu]Lu- EVS459"
}
],
"secondaryOutcomes": [
{
"measure": "Overall response rate (ORR)"
},
{
"measure": "Duration of Response (DOR)"
},
{
"measure": "Disease control rate (DCR)"
},
{
"measure": "Progression free survival (PFS)"
},
{
"measure": "Area Under the Curve (AUC) of [177Lu]Lu-EVS459"
},
{
"measure": "Total body clearance of [177Lu[Lu-EVS459"
},
{
"measure": "Observed maximum plasma concentration (Cmax) of [177Lu]Lu-EVS459"
},
{
"measure": "Volume of distribution during the terminal phase following intravenous elimination (Vz) of [177Lu]Lu-EVS459"
},
{
"measure": "Terminal elimination half-life (T1/2) of [177Lu]Lu-EVS459"
},
{
"measure": "Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA)"
},
{
"measure": "Renal clearance of [177Lu]Lu- EVS459"
},
{
"measure": "Absorbed dose of [177Lu]Lu- EVS459"
},
{
"measure": "Time-activity curves (TACs) related to [177Lu]Lu-EVS459 uptake in organs and tumor lesions"
},
{
"measure": "Incidence and severity of adverse events and serious adverse events of [68Ga]Ga-EVS459"
},
{
"measure": "Visual and quantitative assessment of [68Ga]Ga-EVS459 uptake in normal tissues and tumor lesions over time"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Novartis Pharmaceuticals"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2030-08-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2030-08-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-09-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Pyridoxamine 300mg per day"
},
{
"name": "Placebo 300mg placebo per day"
}
]
},
"conditionsModule": {
"conditions": [
"Type 2 Diabetes",
"Microvascular Function",
"Retinopathy, Diabetic",
"Nephropathy, Diabetic",
"Neuropathy, Diabetic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Maastricht",
"contacts": [
{
"email": "[email protected]",
"name": "CTCM Clinical Trial Center Maastricht",
"phone": "+ 31 (0) 43 387 20 40",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Netherlands",
"facility": "Academic Hospital Maastricht",
"geoPoint": {
"lat": 50.84833,
"lon": 5.68889
},
"state": null,
"status": "RECRUITING",
"zip": "6229 HX"
}
]
},
"descriptionModule": {
"briefSummary": "Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PYRAMID",
"briefTitle": "The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes",
"nctId": "NCT06376240",
"orgStudyIdInfo": {
"id": "NL85203.068.23",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "eGFR"
},
{
"measure": "Microvascular function in skin"
},
{
"measure": "Markers of endothelial function and glycation in blood plasma."
},
{
"measure": "Advanced glycation end products in skin"
},
{
"measure": "Advanced glycation end products in blood plasma and urine"
},
{
"measure": "Adipokines and inflammatory markers in blood plasma"
},
{
"measure": "Methylglyoxal, glyoxal and 3-deoxyglucose in blood plasma."
},
{
"measure": "Markers of dicarbonyl stress and oxidative stress in urine"
},
{
"measure": "Glucose metabolism"
},
{
"measure": "Liver fat"
},
{
"measure": "Systolic and diastolic blood pressure"
},
{
"measure": "Microvascular function eye"
},
{
"measure": "Urinary albumin"
}
],
"primaryOutcomes": [
{
"measure": "Central retinal artery equivalent of the eye"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Diabetes Fonds"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Maastricht University Medical Center"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-21"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "with or without Left Colic Artery Preservation"
}
]
},
"conditionsModule": {
"conditions": [
"Rectal Cancer",
"Left Colic Artery Stenosis (Diagnosis)",
"Robotic Assisted Laparoscopic Surgery"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Yangzhou",
"contacts": null,
"country": "China",
"facility": "Northern Jiangsu People's Hospital Affiliated to Yangzhou University, General Surgery Institute of Yangzhou, Yangzhou University , Yangzhou",
"geoPoint": {
"lat": 32.39722,
"lon": 119.43583
},
"state": "Jiangsu",
"status": null,
"zip": "225001"
}
]
},
"descriptionModule": {
"briefSummary": "Brief Summary\n\nBackground The preservation of the left colic artery (LCA) during rectal cancer resection remains a topic of controversy, and there is a notable absence of robust evidence regarding the outcomes associated with LCA preservation. And the advantages of robotic-assisted laparoscopy (RAL) surgery in rectal resection remain uncertain. The objective of this study was to assess the influence of LCA preservation surgery and RAL surgery on intraoperative and postoperative complications of rectal cancer resection.\n\nMethods Participants who underwent laparoscopic (LSC) or RAL with or without LCA preservation resection for rectal cancer between April 2020 and May 2023 were retrospectively assessed. The patients were categorized into two groups: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA. A one-to-one propensity score-matched analysis was performed to decrease confounding. The primary outcome was operative findings, operative morbidity, and postoperative genitourinary function."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "RETROSPECTIVE"
},
"enrollmentInfo": {
"count": 1164,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Robotic-Assisted or Laparoscopic Radical Resection for Rectal Cancer With or Without Left Colic Artery Preservation",
"nctId": "NCT06376227",
"orgStudyIdInfo": {
"id": "jamesdukeryan",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The incidence of anastomotic leakage in postoperative patients with or without left colic artery preservation."
}
],
"secondaryOutcomes": [
{
"measure": "The genitourinary function of the patients after the radical resection with or without left colic artery preservation."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Northern Jiangsu People's Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-12-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-22"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-05-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Dratumumab / Hyaluronidase Injection [Darzalex Faspro]"
},
{
"name": "Pomalidomide 4 MG"
},
{
"name": "autologous stem cell transplantation (ASCT)"
}
]
},
"conditionsModule": {
"conditions": [
"Light Chain (AL) Amyloidosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Nanjing",
"contacts": [
{
"email": "[email protected]",
"name": "Xianghua Huang, MD",
"phone": "02580862351",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "National Clinical Research Center for Kidney Diseases, Jinling Hospital",
"geoPoint": {
"lat": 32.06167,
"lon": 118.77778
},
"state": "Jiangsu",
"status": "RECRUITING",
"zip": "210016"
}
]
},
"descriptionModule": {
"briefSummary": "This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were divided into three groups: one group received long-term treatment with daratumumab based regimen, and the other group received autologous stem cell transplantation after two standard treatment courses with daratumumab based regimen, and the third group consists of newly diagnosed stage IIIb AL amyloidosis patients who plan to receive DPD treatment. The purpose of this study is to observe the efficacy and safety of Daratumumab, in the treatment of newly diagnosed systemic AL amyloidosis."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Daratumumab for Patients With Light Chain Amyloidosis",
"nctId": "NCT06376214",
"orgStudyIdInfo": {
"id": "2024-02",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Hematological complete response rate"
},
{
"measure": "Organ response rate"
}
],
"secondaryOutcomes": [
{
"measure": "Time to Next Treatment"
},
{
"measure": "Progression-free survival"
},
{
"measure": "Overall survival"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Nanjing University School of Medicine"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-01-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Amphotericin B cholesterol-sulfate complex for injection"
}
]
},
"conditionsModule": {
"conditions": [
"Invasive Fungal Disease"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This study is a prospective, multicenter, single-arm study, that aims to evaluate the efficacy and safety of amphotericin B cholesterol-sulfate complex (ABCD) for injection in the first-line treatment of patients with invasive fungal diseases, hoping to provide a reference for the clinical treatment of invasive fungal diseases. Patients with hematologic diseases who meet the criteria for inclusion and discharge with febrile neutropenia and suspected fungal infection were treated with ABCD antifungal therapy for 14 days while receiving treatment for underlying diseases, and the response rate of treatment was observed."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 125,
"type": "ESTIMATED"
},
"phases": [
"PHASE4"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease",
"nctId": "NCT06376201",
"orgStudyIdInfo": {
"id": "NFEC-2024-018",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Treatment is effective"
}
],
"secondaryOutcomes": [
{
"measure": "Incidence of the single index in the five criteria of treatment success"
},
{
"measure": "Completion rate of ABCD treatment for at least 14 days"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Nanfang Hospital, Southern Medical University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-02"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "communication training"
}
]
},
"conditionsModule": {
"conditions": [
"Communication",
"End of Life",
"Pediatric ALL"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Vienna",
"contacts": null,
"country": "Austria",
"facility": "Medical University of Vienna",
"geoPoint": {
"lat": 48.20849,
"lon": 16.37208
},
"state": null,
"status": null,
"zip": "1090"
}
]
},
"descriptionModule": {
"briefSummary": "Breaking bad news, especially a death notice, is an essential part of the medical profes-sional communication. Being inadequately trained in those skills this may result in un-pleasant psychosocial consequences for everyone involved.\n\nThis prospective, single-center, randomized controlled trial evaluated the delivery of a death notice to simulation parents out of the perspective of these parents (professional actors), the participants (students) and by video analysis. The simulation patient has prior unexpectedly died during a simulated resuscitation. The intervention group broke the bad news after receiving a short communication"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 46,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "SimCom",
"briefTitle": "Improving Breaking Bad News in Pediatrics by Simulated Communication",
"nctId": "NCT06376188",
"orgStudyIdInfo": {
"id": "1582/2021 SimCom",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "score by simulation parents"
}
],
"secondaryOutcomes": [
{
"measure": "score by participants"
},
{
"measure": "score of video analysis"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Medical University of Vienna"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-09-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-08-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2021-09-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Healthy Adults"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Sacramento",
"contacts": [
{
"email": null,
"name": "Kevin Madore, PhD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "UC Davis Imaging Research Center (IRC)",
"geoPoint": {
"lat": 38.58157,
"lon": -121.4944
},
"state": "California",
"status": null,
"zip": "95817"
}
]
},
"descriptionModule": {
"briefSummary": "Healthy volunteers ages 25-40 from the general US population who meet the eligibility criteria and are enrolled will (a) play Lumosity games at least 20 times each in under 60 days and (b) then complete one session of task-based functional magnetic resonance imaging (fMRI) while playing Lumosity games."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "40 Years",
"minimumAge": "25 Years",
"sex": "ALL",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Task Atlas: Study to Develop a Task Atlas of Brain Recruitment During a Digital Game-based Program",
"nctId": "NCT06376175",
"orgStudyIdInfo": {
"id": "LL-016",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "BOLD response during gameplay"
},
{
"measure": "Responder rates"
},
{
"measure": "Structural MRI volumetrics: Volume"
},
{
"measure": "Structural MRI volumetrics: Cortical thickness"
},
{
"measure": "Structural MRI volumetrics: Brain-Predicted Age Difference"
},
{
"measure": "Behavior response: Game score"
},
{
"measure": "BAMS-7 (Brief Attention and Mood Scale of 7 Items)"
},
{
"measure": "VGPQ (Video Game Playing Questionnaire)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Lumos Labs, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-08-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Ziftomenib"
},
{
"name": "Cytarabine"
},
{
"name": "Fludarabine"
}
]
},
"conditionsModule": {
"conditions": [
"Relapsed/Refractory KMT2A-r Acute Leukemia",
"Relapsed/Refractory NUP98-r Acute Leukemia",
"Relapsed/Refractory NPM1-m Acute Leukemia"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK)."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 20,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "21 Years",
"minimumAge": "0 Years",
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia",
"nctId": "NCT06376162",
"orgStudyIdInfo": {
"id": "ITCC-101/APAL2020K",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": null,
"id": "2023-505262-28-00",
"link": null,
"type": "CTIS"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of Participants Who Experience a Dose-limiting Toxicity (DLT)"
},
{
"measure": "Area Under the Plasma Concentration-time Curve (AUC) of Ziftomenib"
}
],
"secondaryOutcomes": [
{
"measure": "Number of Participants Who Experience an Adverse Event (AE)"
},
{
"measure": "Number of AEs by Severity"
},
{
"measure": "Maximum Observed Plasma Concentration (Cmax) of Ziftomenib"
},
{
"measure": "Minimum Observed Plasma Concentration (Cmin) of Ziftomenib"
},
{
"measure": "Time to Cmax (Tmax)"
},
{
"measure": "Truncated AUC (AUC0-t) of Ziftomenib in Combination with FLA Chemotherapy"
},
{
"measure": "Extrapolated AUC (AUC0-∞) of Ziftomenib in Combination with FLA Chemotherapy"
},
{
"measure": "Oral Plasma Clearance (CL/F) of Ziftomenib in Combination with FLA Chemotherapy"
},
{
"measure": "Volume of Distribution (Vz/F) of Ziftomenib in Combination with FLA Chemotherapy"
},
{
"measure": "Terminal Elimination Half-life (t1/2) of Ziftomenib in Combination with FLA Chemotherapy"
},
{
"measure": "HSCT Rate"
},
{
"measure": "Morphological Overall Response Rate (ORR)"
},
{
"measure": "Flow-based ORR"
},
{
"measure": "Flow-based Measurable Residual Disease (MRD) Negativity Rate"
},
{
"measure": "Duration of Response (DOR)"
},
{
"measure": "Event-free Survival (EFS)"
},
{
"measure": "Overall Survival (OS)"
},
{
"measure": "Cumulative Incidence of Relapse (CIR)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Kura Oncology"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "LLS PedAL Initiative, LLC"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-08"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-08"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "M3 Intervention group"
},
{
"name": "M3 Waitlist Group"
}
]
},
"conditionsModule": {
"conditions": [
"Juvenile Idiopathic Arthritis",
"Children",
"Mental Health",
"Mental Well-being"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Hamilton",
"contacts": [
{
"email": "[email protected]",
"name": "Karen Beatie",
"phone": "(905) 521-2100",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Michelle Dr. Batthish",
"phone": "(905) 521-2100",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Michelle Batthish",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Canada",
"facility": "McMaster Children's Hospital,",
"geoPoint": {
"lat": 43.25011,
"lon": -79.84963
},
"state": "Ontario",
"status": null,
"zip": "L8N 3Z5"
},
{
"city": "London",
"contacts": [
{
"email": "[email protected]",
"name": "Sarah Wells",
"phone": "519-685-8500",
"phoneExt": "56816",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Roberta Berard",
"phone": "519-685-8500",
"phoneExt": "52479",
"role": "CONTACT"
},
{
"email": null,
"name": "Roberta Berard, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Canada",
"facility": "London Health Sciences Centre- Children's Hosptial",
"geoPoint": {
"lat": 42.98339,
"lon": -81.23304
},
"state": "Ontario",
"status": null,
"zip": "N6J 4L8"
},
{
"city": "Toronto",
"contacts": [
{
"email": "[email protected]",
"name": "Andrea Knight",
"phone": "(416) 813-1500",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Andrea Dr. Knight",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Canada",
"facility": "Sickids",
"geoPoint": {
"lat": 43.70011,
"lon": -79.4163
},
"state": "Ontario",
"status": null,
"zip": "M5G 1E8"
}
]
},
"descriptionModule": {
"briefSummary": "The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric chronic disease. The child program is designed for children 4-12 years of age, with each lesson including a variety of concrete ways to teach children skills based on their age/developmental level."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "The primary objective is to conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s).\n\nMeasures will be obtained via questionnaires at 3 time points: baseline, 9 weeks and 2 months post-intervention.\n\nAdditionally, at the start of each session, parents will complete a one-page semi-structured questionnaire evaluating treatment fidelity and at home utilization of M3© skills. At the end of each session, parent participants will complete a one-page structured questionnaire providing feedback on the session, and facilitators will complete the M3© Adherence Checklist, evaluating whether planned activities were completed, and any modifications made.",
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": "Participants will be blinded to their group assignment: all participants will be told that they will receive the intervention. Program facilitators will be blinded to participant group assignment order, since sessions for both study arms would run on a rolling basis. The statistician will also be blinded to the group assignment and order.",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 74,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "12 Years",
"minimumAge": "4 Years",
"sex": "ALL",
"stdAges": [
"CHILD"
]
},
"identificationModule": {
"acronym": "M3-JIA",
"briefTitle": "M3-JIA: Making Mindfulness Matter for Children With JIA",
"nctId": "NCT06376149",
"orgStudyIdInfo": {
"id": "124973",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Does M3 have a positive effect on parents' stress"
},
{
"measure": "Does M3 have a positive effect on parents' depression and anxiety"
},
{
"measure": "Does M3 have a positive effect on Child's' depression and anxiety"
},
{
"measure": "Does M3 have a positive effect on children's resiliency"
},
{
"measure": "Does M3 have a positive effect on parent resiliency"
}
],
"primaryOutcomes": [
{
"measure": "conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s)."
}
],
"secondaryOutcomes": [
{
"measure": "Effects of M3 on health related quality of life of children with JIA"
},
{
"measure": "Effects of M3 on health quality of life for parents"
},
{
"measure": "Does M3 have a positive effect on children's severity of JIA"
},
{
"measure": "Does M3 have a positive effect on children's executive function"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Brain Canada"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Lawson Health Research Institute"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-29"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-08"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "BAT8010 for Injection"
},
{
"name": "BAT1006 for Injection"
}
]
},
"conditionsModule": {
"conditions": [
"Advanced Solid Tumors"
]
},
"contactsLocationsModule": null,
"descriptionModule": {
"briefSummary": "This study is a multicenter, open, exploratory Phase Ib/IIa clinical trial in humans The combination of BAT8010 and BAT1006 was administered in patients with locally advanced or metastatic solid tumors(HER-2 expression, including IHC3+, IHC2+/FISH+, and IHC2+/FISH- patients)Tolerance and PK characteristics, to explore the maximum tolerated dose (MTD) and provide recommendations for subsequent clinical studies Recommended dose (RP2D) and rational administration regimen, and preliminary evaluation of antitumor efficacy. There are two main studies In the first stage, the \"3+3\" dose escalation rule is proposed to explore the safety and tolerance of the drug Sex; The second stage selects the appropriate dose and administration according to the preliminary safety and efficacy results of the previous stage The drug regimen and tumor species were expanded to further explore the combination of BAT8010 and BAT1006 for injection，The safety and clinical effectiveness of drug administration provided the basis for the follow-up clinical study."
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 108,
"type": "ESTIMATED"
},
"phases": [
"PHASE1",
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study",
"nctId": "NCT06376136",
"orgStudyIdInfo": {
"id": "BAT-8010+1006-001-CR",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Dose-limiting toxicity (DLT)"
},
{
"measure": "vital signs"
},
{
"measure": "Physical examination"
},
{
"measure": "Adverse events"
},
{
"measure": "Clinical laboratory tests"
},
{
"measure": "Number of participants with abnormal clinical auxiliary tests"
},
{
"measure": "Duration of Response(DOR)"
},
{
"measure": "Disease Control Rate (DCR)"
}
],
"secondaryOutcomes": [
{
"measure": "Pharmacokinetic"
},
{
"measure": "Pharmacokinetic"
},
{
"measure": "Pharmacokinetic"
},
{
"measure": "Pharmacokinetic"
},
{
"measure": "Antibody"
},
{
"measure": "Antibody"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Bio-Thera Solutions"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-12-09"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-05-24"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-30"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": null
},
"conditionsModule": {
"conditions": [
"One-lung Ventilation"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "Bezmialem Vakif University Dragos Hospital",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": "Maltepe",
"status": null,
"zip": "34844"
}
]
},
"descriptionModule": {
"briefSummary": "The cause of hypoxia during one-lung ventilation is a common anaesthetic problem seen during thoracic surgery and is associated with increased fraction of shunted blood. This shunt occurs because the lung not participating in respiration stops saturating the blood with oxygen. The importance of our study is to collect some of the patient's parameters on a nomogram in the preoperative period, to predict the shunt fraction that will occur during one-lung ventilation and to make preparations and interventions accordingly."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Nomogram for Prediction of Alveolo-arterial Gradient During One-lung Ventilation",
"nctId": "NCT06376123",
"orgStudyIdInfo": {
"id": "Nkangarli001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Alveolo-arterial gradient"
},
{
"measure": "Alveolo-arterial gradient"
}
],
"secondaryOutcomes": [
{
"measure": "Alveolo-arterial gradient change"
},
{
"measure": "Alveolo-arterial gradient change"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Bezmialem Vakif University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-09-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Topical Antioxidant Serum"
},
{
"name": "AviClear Laser"
}
]
},
"conditionsModule": {
"conditions": [
"Acne"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This is a split-face, single-blind study assessing the use of an antioxidant serum with a series of acne laser treatments to reduce sebum production in healthy male and female subjects between the ages of 18 and 65 years, inclusive, with Fitzpatrick skin types I-VI."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 10,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production",
"nctId": "NCT06376110",
"orgStudyIdInfo": {
"id": "AviClear-001",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Change in Product Tolerability"
},
{
"measure": "Change in Product Efficacy"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "SkinCeuticals"
}
],
"leadSponsor": {
"class": "NETWORK",
"name": "Austin Institute for Clinical Research"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Lung Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Botucatu",
"contacts": [
{
"email": "[email protected]",
"name": "Erica Hasimoto",
"phone": "(14) 99792-0222",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Brazil",
"facility": "Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB)",
"geoPoint": {
"lat": -22.88583,
"lon": -48.445
},
"state": "São Paulo",
"status": "RECRUITING",
"zip": "18618-686"
}
]
},
"descriptionModule": {
"briefSummary": "Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 1000,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "74 Years",
"minimumAge": "45 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.",
"nctId": "NCT06376097",
"orgStudyIdInfo": {
"id": "D5162R00036",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Absolute number and frequency of false-negative lung nodules ."
}
],
"secondaryOutcomes": [
{
"measure": "Assess adherence to smoking cessation treatment in active smokers who enter screening."
},
{
"measure": "Assessment of morbidity and mortality in patients undergoing invasive procedures, whether diagnostic or therapeutic."
},
{
"measure": "Cost comparasion of treating patients in metastatic setting vs. treating early-stage lung cancer patients, including all costs from the screening program."
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "AstraZeneca"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-01-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-01-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-04-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": null,
"conditionsModule": {
"conditions": [
"Carcinoma, Non-Small-Cell Lung",
"Lung Neoplasms",
"Respiratory Tract Neoplasms",
"Thoracic Neoplasms",
"Neoplasms by Site",
"Neoplasms",
"Lung Diseases",
"Respiratory Tract Diseases",
"Carcinoma, Bronchogenic",
"Bronchial Neoplasms"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shanghai",
"contacts": [
{
"email": "[email protected]",
"name": "Rong LI",
"phone": "+8621-22200000-5451",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "Shanghai Chest Hospital",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": "Shanghai",
"status": null,
"zip": "200030"
}
]
},
"descriptionModule": {
"briefSummary": "To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 700,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "FOREFRONT",
"briefTitle": "Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC",
"nctId": "NCT06376084",
"orgStudyIdInfo": {
"id": "D5161R00055",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Real-World Progression Free Survival (rwPFS)"
}
],
"secondaryOutcomes": [
{
"measure": "Chemotherapy regimen"
},
{
"measure": "Duration of chemotherapy (induction and maintenance cycles)"
},
{
"measure": "Response rate"
},
{
"measure": "Duration of response"
},
{
"measure": "Overall survival (OS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "AstraZeneca"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2028-02-28"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2028-02-28"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-07-24"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "functional endoscopic sinus surgery"
}
]
},
"conditionsModule": {
"conditions": [
"Allergic Fungal Rhinosinusitis"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "This study aims to assess Sinonasal risk factors for occurrence of unilateral versus bilateral allergic fungal rhino sinusitis regarding::\n\n1. anatomical variations and correlate radiological finding with intraoperative finding.\n2. other associated factors like demographic ,environmental, immunological and climatic risk factors ."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CROSSOVER",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
},
"enrollmentInfo": {
"count": 76,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Sinonasal Risk Factors for Occurrence of Unilateral Versus Bilateral Allergic Fungal Rhinosinusitis .",
"nctId": "NCT06376071",
"orgStudyIdInfo": {
"id": "fungal rhinosiusitis",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Sinonasal risk factors for occurrence of unilateral versus bilateral allergic fungal rhinosinusitis"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Assiut University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-05-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Chloroprocaine 1% Injectable Solution"
},
{
"name": "Ropivacaine 0.75% Injectable Solution"
}
]
},
"conditionsModule": {
"conditions": [
"Cesarean Section",
"Local Anesthetic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Athens",
"contacts": [
{
"email": "[email protected]",
"name": "Kassiani Theodoraki, PhD, DESA",
"phone": "6974634162",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Marianna Mavromati, MD",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Greece",
"facility": "Aretaieion University Hospital",
"geoPoint": {
"lat": 37.97945,
"lon": 23.71622
},
"state": null,
"status": "RECRUITING",
"zip": "11528"
}
]
},
"descriptionModule": {
"briefSummary": "This will be a prospective randomized study, aiming at comparing an intrathecal fixed dose of chloroprocaine 1% versus an intrathecal fixed dose of ropivacaine 0.75% in elective cesarean sections"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 60,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "48 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "annie-mariana",
"briefTitle": "Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section",
"nctId": "NCT06376058",
"orgStudyIdInfo": {
"id": "434/06-06-2022",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Time from spinal anesthesia to T10 block (min)"
},
{
"measure": "Time from spinal anesthesia to T4 block (min)"
},
{
"measure": "Time of spinal anesthesia to Bromage =3"
},
{
"measure": "level of sensory block every 3 min"
},
{
"measure": "level of sensory block every 15 min"
},
{
"measure": "highest level of sensory block"
},
{
"measure": "time from spinal anesthesia to highest level of sensory block"
},
{
"measure": "duration of sensory block"
},
{
"measure": "pain at surgical incision"
},
{
"measure": "pain at neonatal delivery"
},
{
"measure": "pain at peritoneal manipulation"
},
{
"measure": "pain at Post Anesthesia Care Unit (PACU) admission"
},
{
"measure": "pain at Post Anesthesia Care Unit (PACU) discharge"
},
{
"measure": "need for rescue analgesia intraoperatively"
},
{
"measure": "Bromage scale every 3 min after spinal anesthesia"
},
{
"measure": "Bromage scale every 15 min"
},
{
"measure": "duration of motor block"
},
{
"measure": "duration of staying in PACU"
}
],
"secondaryOutcomes": [
{
"measure": "Neonatal Apgar score at 1 minute"
},
{
"measure": "Neonatal Apgar score at 5 minutes"
},
{
"measure": "neonatal blood gases"
},
{
"measure": "incidence of neonatal acidosis"
},
{
"measure": "incidence of hypotension"
},
{
"measure": "incidence of bradycardia"
},
{
"measure": "need for vasoconstrictor"
},
{
"measure": "need for atropine"
},
{
"measure": "incidence of nausea/vomiting"
},
{
"measure": "incidence of dizziness"
},
{
"measure": "incidence of drowsiness"
},
{
"measure": "incidence of discomfort"
},
{
"measure": "incidence of shivering"
},
{
"measure": "need for rescue analgesia in PACU"
},
{
"measure": "time from spinal anesthesia to rescue analgesia in PACU"
},
{
"measure": "incidence of neurological symptoms during hospital stay"
},
{
"measure": "incidence of neurological symptoms 2 months after the operation"
},
{
"measure": "incidence of low back pain"
},
{
"measure": "time from spinal anesthesia to mobilization"
},
{
"measure": "mother's satisfaction from anesthesia"
},
{
"measure": "gynecologist's satisfaction"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Aretaieion University Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-01-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Rocatinlimab"
},
{
"name": "Placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Asthma"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 428,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "75 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma",
"nctId": "NCT06376045",
"orgStudyIdInfo": {
"id": "20220093",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Annualized Asthma Exacerbation Rate (AAER) During the Blinded Treatment Period"
}
],
"secondaryOutcomes": [
{
"measure": "Change From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1)"
},
{
"measure": "Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period"
},
{
"measure": "Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 48"
},
{
"measure": "Change From Baseline in Pre-BD FEV1"
},
{
"measure": "Change From Baseline in Asthma Symptom Diary (ASD) Score"
},
{
"measure": "Number of Participant Achieving ACQ-6 Response at Week 48"
},
{
"measure": "Change From Baseline in ACQ-6"
},
{
"measure": "Change From Baseline in Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ (S)) Self-Administered Score"
},
{
"measure": "Number of Participants Achieving AQLQ (S) Response at Week 48"
},
{
"measure": "Annualized Rate of Asthma Exacerbation Leading to Hospitalization or Emergency Room Visits During the Blinded Treatment Period"
},
{
"measure": "Time to First Asthma Exacerbation Event"
},
{
"measure": "Time to First CompEx Event"
},
{
"measure": "Number of Participants with a CompEx Event During the Double Blinded Treatment Period"
},
{
"measure": "Annualized Rate of CompEx Events"
},
{
"measure": "Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels"
},
{
"measure": "Serum Rocatinlimab Concentrations"
},
{
"measure": "Trough Concentration (Ctrough) of Rocatinlimab"
},
{
"measure": "Number of Participants with Treatment-emergent Adverse Events"
},
{
"measure": "Number of Participants with Serious Adverse Events"
},
{
"measure": "Number of Participants with Anti-rocatinlimab Antibody Formation"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Amgen"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-10-02"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-08-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "EndeavorOTC®"
}
]
},
"conditionsModule": {
"conditions": [
"Attention",
"Cognition",
"University Students"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cheektowaga",
"contacts": [
{
"email": "[email protected]",
"name": "Laura Pietak",
"phone": "716-961-2869",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Villa Maria College",
"geoPoint": {
"lat": 42.90339,
"lon": -78.75475
},
"state": "New York",
"status": "RECRUITING",
"zip": "14225"
},
{
"city": "Putney",
"contacts": [
{
"email": "[email protected]",
"name": "Rick Bryck, PhD",
"phone": "802-387-6306",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "Landmark College",
"geoPoint": {
"lat": 42.9748,
"lon": -72.52176
},
"state": "Vermont",
"status": "RECRUITING",
"zip": "05346"
}
]
},
"descriptionModule": {
"briefSummary": "The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "CROSSOVER",
"interventionModelDescription": "Eligible students will be randomized\\* to two cohorts: the first will receive immediate access to AKL-T01, and the second will complete weekly online surveys and receive access to AKL-T01 after the first group has completed the recommended 6 weeks of use. Regardless of group assignment, all participants will receive full 12-weeks of access to AKL-T01 during the course of the study.\n\n\\*Depending on enrollment numbers for a given semester (e.g., if \\<100 students are enrolled and the study is underpowered to conduct between-group comparisons), all participants may be assigned to receive treatment immediately (i.e., single-arm design) and primary study hypotheses may be evaluated according to within-person changes in outcomes.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "OTHER",
"timePerspective": null
},
"enrollmentInfo": {
"count": 500,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "EndeavorOTC® Research Study in College Students",
"nctId": "NCT06376032",
"orgStudyIdInfo": {
"id": "Akili-068",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "System Usability Scale (SUS)"
}
],
"primaryOutcomes": [
{
"measure": "Computerized Adaptive Test, Mental Health (CAT-MH®)"
},
{
"measure": "PROMIS Cognitive Function v2.0 - Short Form"
},
{
"measure": "PROMIS Satisfaction with Participation in Discretionary Social Activities (v1.0)"
},
{
"measure": "General Academic Self-Efficacy scale (GASE)"
},
{
"measure": "Mental Health Quality of Life Scale (MHQoL)"
},
{
"measure": "Adult ADHD Self-Report Scale (ASRS)"
},
{
"measure": "Patient Health Questionnaire-4 (PHQ-4)"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Landmark College"
},
{
"name": "Villa Maria College"
}
],
"leadSponsor": {
"class": "INDUSTRY",
"name": "Akili Interactive Labs, Inc."
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-01-10"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "solitary Implant loading with ball attachment"
},
{
"name": "splinted Implant loading with intra oral welding"
},
{
"name": "complete denture"
}
]
},
"conditionsModule": {
"conditions": [
"Edentulous Jaw"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Cairo",
"contacts": null,
"country": "Egypt",
"facility": "Faculty of Dentistry Ain Shams University",
"geoPoint": {
"lat": 30.06263,
"lon": 31.24967
},
"state": null,
"status": null,
"zip": "11361"
}
]
},
"descriptionModule": {
"briefSummary": "complete denture wearers struggle to eat well with their dentures due to poor denture retention, stability, and occlusal disharmony. So, the current study protocol aims to compare the occlusion/ disocclusion time in immediately loaded implant retained overdentures supported by two interforaminal implants; splinted versus non splinted dental implants compared to the conventional complete denture."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "parallel assignment of the participants in ratio 1:1:1 will take place. For allocation concealment, opaque sealed envelopes will be used.",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": "the statistician will be the only one to be blinded",
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 27,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "70 Years",
"minimumAge": "50 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Occlusion and Disocclusion Time in Immediately Loaded Overdentures Supported by Two Splinted Versus Non Splinted Interforaminal Implants",
"nctId": "NCT06376019",
"orgStudyIdInfo": {
"id": "FDASU-RecID11352",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Assessment of occlusion/disocclusion time"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Ain Shams University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-09-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-08-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-25"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "EMR STAT - Survey"
}
]
},
"conditionsModule": {
"conditions": [
"Competence",
"Assessment, Self"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Orlando",
"contacts": null,
"country": "United States",
"facility": "AdventHealth Orlando",
"geoPoint": {
"lat": 28.53834,
"lon": -81.37924
},
"state": "Florida",
"status": null,
"zip": "32804"
}
]
},
"descriptionModule": {
"briefSummary": "Quality improvement project with the aim to use a standardized assessment tool (EMR-STAT) to establish learning curves and competence thresholds for key cognitive and technical colorectal EMR core skills among advanced endoscopy trainees (AETs)."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 42,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "EMR-STAT",
"briefTitle": "Evaluating Learning Curves and Competence in Colorectal Endoscopic Mucosal Resection Among Advanced Endoscopy Trainees",
"nctId": "NCT06376006",
"orgStudyIdInfo": {
"id": "1798538",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Primary Endpoint"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Duke University"
},
{
"name": "University of South Florida"
},
{
"name": "Stony Brook University"
},
{
"name": "Atrium Medical Center"
},
{
"name": "Hofstra University"
},
{
"name": "Long Island Jewish Medical Center"
},
{
"name": "Vanderbilt University"
},
{
"name": "Yale University"
},
{
"name": "Columbia University"
},
{
"name": "Geisinger Clinic"
},
{
"name": "Unity Health Toronto"
},
{
"name": "University of Virginia"
},
{
"name": "Baylor University"
},
{
"name": "University of Kentucky"
},
{
"name": "Cedars-Sinai Medical Center"
},
{
"name": "University of Chicago"
},
{
"name": "University of California, Irvine"
},
{
"name": "University of Alabama at Birmingham"
},
{
"name": "Beth Israel Deaconess Medical Center"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "AdventHealth"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-12-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-24"
},
"overallStatus": "ACTIVE_NOT_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-05-11"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "ADI-001"
},
{
"name": "Fludarabine"
},
{
"name": "Cyclophosphamide"
}
]
},
"conditionsModule": {
"conditions": [
"Lupus Nephritis",
"Autoimmune Diseases"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion safety/efficacy study in patients with lupus nephritis. The study will consist of different periods including screening, lymphodepletion, treatment, and follow-up"
},
"designModule": {
"designInfo": {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SEQUENTIAL",
"interventionModelDescription": "3+3 Dose Escalation Design",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "A Phase 1 Study of ADI-001 in Lupus Nephritis",
"nctId": "NCT06375993",
"orgStudyIdInfo": {
"id": "ADI-202300103",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort"
},
{
"measure": "Proportion of treatment emergent and treatment related adverse events"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "INDUSTRY",
"name": "Adicet Bio, Inc"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-12"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-12"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Intraoperative Mechanical Ventilation Strategies"
}
]
},
"conditionsModule": {
"conditions": [
"Lung Injury",
"Pulmonary Complication"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": null,
"country": "Turkey",
"facility": "Ankara Oncology Training and Research Hospital",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": null,
"zip": "06200"
}
]
},
"descriptionModule": {
"briefSummary": "This study investigates the relationship between intraoperative mechanical power and postoperative pulmonary complications in patients undergoing major abdominal surgery. We record mechanical ventilation parameters and surgical characteristics, assessing the incidence of pulmonary complications within 24 hours postoperatively"
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 207,
"type": "ACTUAL"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Intraoperative Mechanical Power and Ventilation-Associated Lung Injury: Assessing Complications",
"nctId": "NCT06375980",
"orgStudyIdInfo": {
"id": "ANKARA_OR_MP",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Relationship between mechanical power and postoperative pulmonary complications"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2022-12-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2022-12-31"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-04-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Endoscopic biliary drainage"
},
{
"name": "Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)"
},
{
"name": "Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)"
}
]
},
"conditionsModule": {
"conditions": [
"Malignant Biliary Obstruction",
"Biliary Tract Neoplasms",
"Pancreatic Cancer Non-resectable"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "L'Hospitalet De Llobregat",
"contacts": [
{
"email": "[email protected]",
"name": "Joan B Gornals, PhD",
"phone": "+34 93 260 76 82",
"phoneExt": "2624",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Julia Escuer Turu, MD",
"phone": "+34 618 27 28 24",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Maria Puigcerver Mas, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Sandra Maisterra, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Albert Garcia-Sumalla, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Julio G Velasquez-Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Daniel Luna-Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Carme Loras, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Charly Guarner Argente, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Juan J Vila, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose R Aparicio, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose Lariño, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Rafa Pedraza, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Antonio Rodriguez D'Jesus, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Alberto Alvarez, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Vicente Sanchiz, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "Hospital Universitari de Bellvitge",
"geoPoint": {
"lat": 41.35967,
"lon": 2.10028
},
"state": "Barcelona, Catalonia",
"status": null,
"zip": "08907"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 128,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "100 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "CARPEGIEM",
"briefTitle": "EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)",
"nctId": "NCT06375967",
"orgStudyIdInfo": {
"id": "CARPEGIEM",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "SAFETY (ADVERSE EVENTS)"
},
{
"measure": "Recurrent biliary obstruction"
}
],
"secondaryOutcomes": [
{
"measure": "CLINICAL SUCCESS"
},
{
"measure": "TECHNICAL SUCCESS"
},
{
"measure": "BILIARY REINTERVENTIONS (BRI)"
},
{
"measure": "HOSPITAL STAY"
},
{
"measure": "MORTALITY"
},
{
"measure": "COST ANALYSIS"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Hospital Clínico Universitario de Valencia"
},
{
"name": "Hospital General Universitario de Alicante"
},
{
"name": "Hospital Mutua de Terrassa"
},
{
"name": "Hospital Universitario Ramon y Cajal"
},
{
"name": "Hospital General Universitario de Castellón"
},
{
"name": "Complejo Hospitalario de Navarra"
},
{
"name": "University Hospital Virgen de las Nieves"
},
{
"name": "Hospital de Sant Pau"
},
{
"name": "University of Salamanca"
},
{
"name": "Complejo Hospitalario Universitario de Santiago"
},
{
"name": "Complejo Hospitalario Universitario de Vigo"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Universitari de Bellvitge"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-06"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-06"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Endoscopic biliary drainage"
},
{
"name": "Self-expandable metallic stent (SEMS)"
},
{
"name": "Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)"
}
]
},
"conditionsModule": {
"conditions": [
"Malignant Biliary Obstruction",
"Pancreatic Cancer",
"Biliary Tract Neoplasms"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "L'Hospitalet de Llobregat",
"contacts": [
{
"email": "[email protected]",
"name": "Joan B Gornals, MD, PhD",
"phone": "+ 34 93 260 7682",
"phoneExt": "2624",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Maria Puigcerver-Mas, MD",
"phone": "+34 687332007",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Julia Escuer, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Sandra Maisterra, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Julio G Velasquez-Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Albert Garcia-Sumalla, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Daniel Luna-Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Berta Laquente, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Juli Busquets, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Carme Loras, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Juan J Vila, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose Lariño, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "VIcente Sanchiz, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose R Aparicio, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Eduardo Redondo, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Charly Guarner-Argente, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Antonio Rodriguez D'Jesus, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Alberto Alvarez, MD, pHD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "Hospital Universitari de Bellvitge",
"geoPoint": {
"lat": 41.35967,
"lon": 2.10028
},
"state": "Barcelona",
"status": null,
"zip": "08907"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and chemotherapy start in patients with borderline distal malignant biliary obstruction."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 96,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)",
"nctId": "NCT06375954",
"orgStudyIdInfo": {
"id": "CARPEDIEM-2",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Delay in days between endoscopic biliary drainage and chemotherapy treatment start"
}
],
"secondaryOutcomes": [
{
"measure": "Technical success"
},
{
"measure": "Clinical success"
},
{
"measure": "AE - biliary drainage"
},
{
"measure": "AE - surgery"
},
{
"measure": "Delay in days between endoscopic biliary drainage and cephalic duodenopancreatectomy (CDP)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Hospital Mutua de Terrassa"
},
{
"name": "Hospital Clínico Universitario de Valencia"
},
{
"name": "Hospital General Universitario de Alicante"
},
{
"name": "Hospital Universitario Ramon y Cajal"
},
{
"name": "Hospital General Universitario de Castellón"
},
{
"name": "Hospital Álvaro Cunqueiro"
},
{
"name": "Complejo Hospitalario Universitario de Santiago"
},
{
"name": "University Hospital Virgen de las Nieves"
},
{
"name": "Complejo Hospitalario de Navarra"
},
{
"name": "Hospital de Sant Pau"
},
{
"name": "University of Salamanca"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Universitari de Bellvitge"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Observational"
}
]
},
"conditionsModule": {
"conditions": [
"Angiosarcoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milano",
"contacts": [
{
"email": null,
"name": "Palassini Elena",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Italy",
"facility": "IRCCS Istituto Nazionale Tumori - Milano",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": "RECRUITING",
"zip": "20133"
}
]
},
"descriptionModule": {
"briefSummary": "This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers. Patients will be treated according to clinical practice of the center and according to ISG clinical recommendations on localized AS."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "OTHER",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 250,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": null,
"sex": "ALL",
"stdAges": [
"CHILD",
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "ProStars",
"briefTitle": "Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars",
"nctId": "NCT06375941",
"orgStudyIdInfo": {
"id": "ProStars",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Demographic characteristics"
},
{
"measure": "General characteristics"
},
{
"measure": "Cancer data"
},
{
"measure": "Origin of Tumor"
},
{
"measure": "Tumor characteristics"
},
{
"measure": "Tumor size"
},
{
"measure": "Tumor aspects"
},
{
"measure": "Pathological characteristics"
},
{
"measure": "Tumor phenotype"
},
{
"measure": "Molecular characteristics"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "NETWORK",
"name": "Italian Sarcoma Group"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2034-04-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2029-04-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-29"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Endoscopic biliary drainage"
},
{
"name": "Self-expandable metallic stent (SEMS)"
},
{
"name": "Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)"
}
]
},
"conditionsModule": {
"conditions": [
"Malignant Biliary Obstruction",
"Pancreatic Cancer Resectable",
"Biliary Tract Neoplasms"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "L'Hospitalet de Llobregat",
"contacts": [
{
"email": "[email protected]",
"name": "Joan B Gornals, MD, PhD",
"phone": "+34 93 260 76 82",
"phoneExt": "2624",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Maria Puigcerver-Mas, MD",
"phone": "+34 687332007",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Julia Escuer-Turu, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Daniel Luna Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Albert Sumalla, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Berta Laquente, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Juli Busquets, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Julio Velasquez Rodriguez, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Sandra Maisterra, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
},
{
"email": null,
"name": "Carme Loras, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Charly Guarner Argente, MD, PHD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose Lariño, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Rafael Pedraza, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Jose Ramon Aparicio, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Vicente Sanchiz, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Eduardo Redondo, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Juan J Vila, MD, PhD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "Hospital Universitari de Bellvitge",
"geoPoint": {
"lat": 41.35967,
"lon": 2.10028
},
"state": "Barcelona, Catalonia",
"status": null,
"zip": "08907"
}
]
},
"descriptionModule": {
"briefSummary": "The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and surgery in patients with resectable distal malignant biliary obstruction."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 44,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)",
"nctId": "NCT06375928",
"orgStudyIdInfo": {
"id": "CARPEDIEM-1",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Delay in days between endoscopic biliary drainage and cephalic duodenopancreatectomy (CDP)"
}
],
"secondaryOutcomes": [
{
"measure": "Technical success"
},
{
"measure": "Clinical success"
},
{
"measure": "AE - biliary drainage"
},
{
"measure": "AE - surgery"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Hospital Mutua de Terrassa"
},
{
"name": "Hospital Clínico Universitario de Valencia"
},
{
"name": "Hospital General Universitario de Alicante"
},
{
"name": "Hospital Universitario Ramon y Cajal"
},
{
"name": "Hospital General Universitario de Castellón"
},
{
"name": "Hospital Álvaro Cunqueiro"
},
{
"name": "Complejo Hospitalario Universitario de Santiago"
},
{
"name": "University Hospital Virgen de las Nieves"
},
{
"name": "Complejo Hospitalario de Navarra"
},
{
"name": "Hospital de Sant Pau"
},
{
"name": "University of Salamanca"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Universitari de Bellvitge"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-05-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-02-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "radioembolization with Y-90"
},
{
"name": "Durvalumab"
},
{
"name": "Cisplatin"
},
{
"name": "Gemcitabine"
}
]
},
"conditionsModule": {
"conditions": [
"Intrahepatic Cholangiocarcinoma"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Milano",
"contacts": [
{
"email": "[email protected]",
"name": "Francesco De Cobelli, MD",
"phone": "+39022643",
"phoneExt": "2529",
"role": "CONTACT"
},
{
"email": "[email protected]",
"name": "Stephanie Steidler, PhD",
"phone": "+39022643",
"phoneExt": "6111",
"role": "CONTACT"
},
{
"email": null,
"name": "Francesco De Cobelli, MD",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"email": null,
"name": "Francesca Ratti, MD",
"phone": null,
"phoneExt": null,
"role": "SUB_INVESTIGATOR"
}
],
"country": "Italy",
"facility": "Department of Radiology, IRCCS Ospedale San Raffaele",
"geoPoint": {
"lat": 45.46427,
"lon": 9.18951
},
"state": null,
"status": null,
"zip": "20132"
}
]
},
"descriptionModule": {
"briefSummary": "Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases. Even though overall disease burden of cancer may have decreased due to a higher degree of awareness, the availability of high-quality healthcare and early diagnosis may become challenging in certain neoplasms. Cholangiocarcinoma is usually diagnosed at advanced stages due to non-specific presentation and is frequently refractory to chemotherapy, causing a massive impact on patients and their families. Surgery is currently the only curative treatment but is available to only approximately 30% of patients. The combination of interventional- and immune-oncology to standard of care creates the perfect substrate for synergistic mechanisms to fight tumor growth; in situ cell death following transarterial embolization(TARE) elicits immune mediated response, inflammatory response and biomarkers of oxidative stress and increases antigen presenting T-cells which an anti-anti progam death ligand (PD-L)1 can bind to; standard of care can then add on with its known effects.The rationale of a combined- locoregional and systemic - treatment lies in the synergistic effects of each of the treatments."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 33,
"type": "ESTIMATED"
},
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "PM-CARE",
"briefTitle": "Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy",
"nctId": "NCT06375915",
"orgStudyIdInfo": {
"id": "PM-CARE",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Italian Ministry of Health",
"id": "PNRR-MAD-2022-12375905",
"link": null,
"type": "OTHER_GRANT"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Overall response rate (ORR)"
},
{
"measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"
}
],
"secondaryOutcomes": [
{
"measure": "Median progression free survival"
},
{
"measure": "Overall response rate"
},
{
"measure": "Overall response rate"
},
{
"measure": "Overall response rate"
},
{
"measure": "Overall response rate"
},
{
"measure": "Tumor circulating markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor circulating markers"
},
{
"measure": "Tumor tissue based evaluation"
},
{
"measure": "Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor tissue-based markers tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Tumor tissue-based markers tumor circulating markers tumor tissue-based markers"
},
{
"measure": "Quantitative imaging based biomarkers"
},
{
"measure": "Quantitative biomarkers"
},
{
"measure": "Overall Survival (OS)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Cardarelli Hospital"
},
{
"name": "A.O. Ospedale Papa Giovanni XXIII"
},
{
"name": "AOU Pisana, Pisa, Italy"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Francesco De Cobelli"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "PragmaCom"
}
]
},
"conditionsModule": {
"conditions": [
"Schizophrenia; Psychosis"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Tracking down the difficulties in metaphor comprehension experienced by individuals with schizophrenia across different metaphor types and exploring the neurological correlates via EEG recording technique"
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 64,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "FRAME",
"briefTitle": "The Fragility of Metaphors (FraMe): Learning, Loosing, and How to Train Them",
"nctId": "NCT06375902",
"orgStudyIdInfo": {
"id": "2022289RNA",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Tracking down the difficulties in metaphor comprehension via a behavioural task"
},
{
"measure": "Tracking down the difficulties in metaphor comprehension via task during electrophysiological recording"
}
],
"secondaryOutcomes": [
{
"measure": "Evaluation of psychopathology"
},
{
"measure": "Evaluation of cognition"
},
{
"measure": "Evaluation of Theory of Mind"
},
{
"measure": "Evaluation of functioning"
},
{
"measure": "Evaluate the efficacy of a rehabilitative training in restoring metaphor comprehension ability"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "IRCCS San Raffaele"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-10"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-10"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "blood test"
}
]
},
"conditionsModule": {
"conditions": [
"Aneuvrysmal Subarachnoid Hemorrhage",
"Delayed Cerebral Ischemia",
"Endotheliopathy",
"Platelets Kinetic"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Bron",
"contacts": [
{
"email": "[email protected]",
"name": "Nicolas Chardon, MD;Msc",
"phone": "683396245",
"phoneExt": "33",
"role": "CONTACT"
},
{
"email": null,
"name": "Nicolas Chardon, MD;msc",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "Anaesthesiology and Intensive Care medicine department, Pierre Wertheimer hospital",
"geoPoint": {
"lat": 45.73333,
"lon": 4.91667
},
"state": "Auvergne-Rhône-Alpes",
"status": null,
"zip": "69005"
},
{
"city": "Bron",
"contacts": [
{
"email": "[email protected]",
"name": "Nicolas Chardon, MD;Msc",
"phone": "683396245",
"phoneExt": "33",
"role": "CONTACT"
},
{
"email": null,
"name": "Nicolas Chardon, MD;Msc",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "France",
"facility": "Neurovascular intensive care unit department, Pierre Wertheimer hospital",
"geoPoint": {
"lat": 45.73333,
"lon": 4.91667
},
"state": "Auvergnes-Rhones-Alpes",
"status": null,
"zip": "69005"
}
]
},
"descriptionModule": {
"briefSummary": "Aneurysmal subarachnoid haemorrhage is a complex pathology, the pathophysiology of which is still imperfectly understood. Its morbidity and mortality remain significant. In addition to the damage sustained by the brain in the immediate aftermath of aneurysmal rupture, which is inaccessible to life-saving treatment, a significant proportion of lesions occur at a distance from the initial event. Delayed cerebral ischaemia is one of the most morbid complications. It combines an inflammatory pattern with vascular dysfunction and neuronal excitotoxicity, leading to avoidable secondary neuronal loss.\n\nVascular dysfunction is mediated by a loss of homeostasis between endothelial cells and figurative blood cells, including platelets. However, the interrelationship between these elements and the precise chronology of the dysfunction remain imperfectly described to date.\n\nIt therefore seems appropriate to propose temporal monitoring of platelet activation kinetics over time, combined with concomitant collection of markers of endothelial damage, in order to clarify the vascular chronobiology of this pathology."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 40,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": "APICRASH",
"briefTitle": "Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage",
"nctId": "NCT06375889",
"orgStudyIdInfo": {
"id": "69HCL24_0250",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "ID-RCB",
"id": "2024-A00796-41",
"link": null,
"type": "OTHER"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "The difference in the percentage of platelets expressing P-selectin, reflecting their irreversible activation."
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hospices Civils de Lyon"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-06-13"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-06-13"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-13"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Single-session intervention (SSI)"
}
]
},
"conditionsModule": {
"conditions": [
"Domestic Violence"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "New Haven",
"contacts": [
{
"email": "[email protected]",
"name": "Ashley Clayton",
"phone": "203-623-9830",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "United States",
"facility": "The Consultation Center at Yale",
"geoPoint": {
"lat": 41.30815,
"lon": -72.92816
},
"state": "Connecticut",
"status": null,
"zip": "06511"
}
]
},
"descriptionModule": {
"briefSummary": "The purpose of this study is to develop a brief, self-guided single-session intervention (SSI) that targets the development of, or increase in, hope, and pilot test it for the primary outcomes of feasibility, acceptability/likeability, safety, and changes in hope, and the secondary outcomes of self-worth, empowerment, and emotional wellbeing among women experiencing intimate partner violence (IPV). The study will be conducted in 2 stages: intervention development (Intervention Development Stage), and pilot testing the intervention (Pilot Stage). The focus of this registration is the Pilot Stage."
},
"designModule": {
"designInfo": {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 65,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Single Session Intervention to Promote Hope",
"nctId": "NCT06375876",
"orgStudyIdInfo": {
"id": "2000034173",
"link": null,
"type": null
},
"secondaryIdInfos": [
{
"domain": "Office on Violence Against Women (OVW)",
"id": "15JOVW-22-GG-04755-STOP",
"link": null,
"type": "OTHER_GRANT"
}
]
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Feasibility assessed by percent enrolled"
},
{
"measure": "Feasibility assessed by time to complete"
},
{
"measure": "Feasibility assessed by post-intervention survey/process supplement"
},
{
"measure": "Acceptability/likability assessed using the Program Feeback Scale"
},
{
"measure": "Safety assessed using end of study survey"
},
{
"measure": "Change in Hope assessed using Herth Hope Index"
},
{
"measure": "Change in Hope assessed using Trait Hope Scale"
},
{
"measure": "Change in Hope assessed using Beck Hopelessness Scale (single item)"
}
],
"secondaryOutcomes": [
{
"measure": "Change in Self-worth"
},
{
"measure": "Change in Empowerment assessed using The Personal Progress Scale-Revised (PPS-R)"
},
{
"measure": "Change in Emotional wellbeing measured by the Patient Health Questionnaire-2 (PHQ-2)"
},
{
"measure": "Change in Emotional wellbeing measured by the State Joy Scale"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Office on Violence Against Women (OVW)"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Yale University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-04"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-26"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-04"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "QT and QTc interval"
}
]
},
"conditionsModule": {
"conditions": [
"Anesthesia, Spinal",
"Sevoflurane",
"Long QT Syndrome"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "Health Science University, Haseki Training and Research Hospital",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": null,
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "QT interval, defined as the time between the beginning of the QRS complex and the end of the T wave in electrocardiography (ECG), is an indicator of depolarization and repolarization of the myocardium.11 Prolongation of the heart rate corrected QT (QTc) interval reflects electrical instability of ventricles and is associated with life-threatening ventricular arrhythmias, including torsade de pointes, ventricular fibrillation and sudden cardiac death.\n\nSpinal anesthesia can cause profound prolongation of the QTc interval due to disparity between lumbar and thoracic sympathetic activity following subarachnoid block. Meanwhile inhalational anesthetics, sevoflurane, isoflurane, and desflurane are known to prolong QTc interval and intravenous anesthetics such as propofol, thiopental, etomidate and ketamin can also cause remarkable prolongation of the QTc interval. Moreover laryngoscopy and intubation may contribute to prolongation of the QTc interval because of the sympathetic stimulation.\n\nOver the years it has been occurred an increase in the proportion of elderly population requiring surgical anesthesia. The incidence of ventricular arrhythmias increases in advancing age even in the absence of underlying heart disease and elderly patients have reduced physiological functions and poor tolerance to anesthesia. However the choice of anesthesia type is critical in this population.\n\nTo the best of knowledge, there was no published study to compare spinal anesthesia and inhalational anesthesia in elderly patients with regard to the QT interval changes. Investigators aimed to investigate the effects of spinal anesthesia on QT, QTc intervals and to compare general anesthesia with sevofluran in elderly patients."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "DIAGNOSTIC",
"timePerspective": null
},
"enrollmentInfo": {
"count": 58,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "QT Changes in Geriatric Patients: a Comparison of Spinal and General Anesthesia",
"nctId": "NCT06375863",
"orgStudyIdInfo": {
"id": "44-2023",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "QTc interval"
}
],
"secondaryOutcomes": [
{
"measure": "QT"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Haseki Training and Research Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2023-05-29"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-05-29"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-03-29"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Sesame oil"
},
{
"name": "Saline solution"
}
]
},
"conditionsModule": {
"conditions": [
"Phlebitis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Santander",
"contacts": [
{
"email": "[email protected]",
"name": "Virginia Meneses Campos",
"phone": "+34942202520",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Virginia Meneses Campos",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "Spain",
"facility": "Hospital Universitario Marqués de Valdecilla",
"geoPoint": {
"lat": 43.46472,
"lon": -3.80444
},
"state": "Cantabria",
"status": "RECRUITING",
"zip": "39008"
}
]
},
"descriptionModule": {
"briefSummary": "Cancer is a disease that, despite having a higher cure rate, is currently on the rise, with an increase in the number of diagnoses.\n\nFor the treatment of these patients a venous access is required, which in the first treatments is of peripheral insertion. These peripheral venous catheter in combination with the highly aggressive treatments for the veins are the cause of the appearance of chemical phlebitis.\n\nPhlebitis is an inflammation caused by a combination of factors, whether chemical, perfusion of irritating medication; mechanical, due to the puncture site, type and fixation of the catheter and infectious, caused by the colonization of pathogenic agents whose origin is the skin and that migrate inward.\n\nPhlebitis involves an injury to the wall of the vein, and consequently, the patient will also be at risk of thrombus formation, which in turn leads to thrombophlebitis, deep vein thrombosis or pulmonary embolism.\n\nThe existence of phlebitis involves intense and constant pain, with increased sensitivity and a sensation of heat and swelling.\n\nWith the use of topical sesame oil, and thanks to its anti-inflammatory properties, the investigators intend to study whether it is effective in preventing the appearance of phlebitis."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
},
"enrollmentInfo": {
"count": 300,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.",
"nctId": "NCT06375850",
"orgStudyIdInfo": {
"id": "Effects of topical sesame oil",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Number of phlebitis in oncology patients with peripheral catheter to whom sesame oil is applied topically"
}
],
"secondaryOutcomes": [
{
"measure": "Other adverse effects that appear in relation to the topical application of sesame oil in patients with peripheral catheters"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hospital Universitario Marqués de Valdecilla"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2025-05-11"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2025-02-11"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2022-06-05"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "an alkasite-based restorative material"
},
{
"name": "hybrid resin composite"
},
{
"name": "a highly filled flowable resin composite"
}
]
},
"conditionsModule": {
"conditions": [
"Tooth Diseases"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Ankara",
"contacts": [
{
"email": null,
"name": "Fatma Oz",
"phone": null,
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "Turkey",
"facility": "Hacettepe University",
"geoPoint": {
"lat": 39.91987,
"lon": 32.85427
},
"state": null,
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The clinical performance of an an alkasite-based restorative material and two different resin composites will be evaluated and compared in non-carious cervical lesions. After recruiting participants with at least three non-carious cervical lesions, all restorations will be placed by a single clinician. Lesions will be divided in three groups: an alkasite-based restorative material (Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)), hybrid resin composite (Gradia Direct Anterior, GC, Tokyo, Japan (GD)) and a highly filled flowable resin composite ((G-aenial Universal Flo, GC, Tokyo, Japan (GF)). All restorative procedures will be conducted according to manufacturers' instructions. Restorations will be scored using FDI criteria. Descriptive statistics will be performed using chi-square tests."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 33,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "65 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Comparative Evaluation of an Alkasite-based Restorative Material and Two Different Resin Composites",
"nctId": "NCT06375837",
"orgStudyIdInfo": {
"id": "bioactive-NCCLs",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": [
{
"measure": "Clinical performances of different restorative systems according to FDI criteria (Biological properties)"
}
],
"primaryOutcomes": [
{
"measure": "Clinical performances of different restorative systems according to FDI criteria (Esthetic properties)"
}
],
"secondaryOutcomes": [
{
"measure": "Clinical performances of different restorative systems according to FDI criteria (Functional properties)"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hacettepe University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-15"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2024-06-15"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-04-15"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Bufei Recipe"
},
{
"name": "Bufei Recipe placebo"
}
]
},
"conditionsModule": {
"conditions": [
"Preserved Ratio Impaired Spirometry"
]
},
"contactsLocationsModule": {
"locations": null
},
"descriptionModule": {
"briefSummary": "Establish early TCM prevention and treatment program to reduce the incidence rate of COPD."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "DOUBLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 1100,
"type": "ESTIMATED"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "18 Years",
"sex": "ALL",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Bufei Recipe Reduces the Incidence Rate of COPD",
"nctId": "NCT06375824",
"orgStudyIdInfo": {
"id": "TCM for Pre-COPD",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Incidence rate of COPD"
}
],
"secondaryOutcomes": [
{
"measure": "FVC"
},
{
"measure": "FEV1"
},
{
"measure": "FEV1% pred"
},
{
"measure": "FEV1/FVC"
},
{
"measure": "IPAG-Q"
},
{
"measure": "LFQ"
},
{
"measure": "COPD-PS"
},
{
"measure": "CAT"
},
{
"measure": "SF-36"
},
{
"measure": "Clinical symptoms"
},
{
"measure": "Biochemical indicators"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "West China Hospital"
},
{
"name": "The First Affiliated Hospital of Zhejiang Chinese Medical University"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Henan University of Traditional Chinese Medicine"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2027-10-31"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "NOT_YET_RECRUITING",
"primaryCompletionDateStruct": {
"date": "2027-04-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-05-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Elagolix 200 MG"
},
{
"name": "Placebo or SOC IVF"
}
]
},
"conditionsModule": {
"conditions": [
"Infertility",
"Endometriosis"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Aurora",
"contacts": [
{
"email": "[email protected]",
"name": "Katherine Kuhn",
"phone": "303-724-5276",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Nanette Santoro",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "University of Colorado Department of Obstetrics & Gynecology",
"geoPoint": {
"lat": 39.72943,
"lon": -104.83192
},
"state": "Colorado",
"status": "RECRUITING",
"zip": "80045"
},
{
"city": "New Haven",
"contacts": [
{
"email": "[email protected]",
"name": "Michele Frank",
"phone": "203-785-6949",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Hugn Taylor",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences",
"geoPoint": {
"lat": 41.30815,
"lon": -72.92816
},
"state": "Connecticut",
"status": "RECRUITING",
"zip": "06520"
},
{
"city": "Chicago",
"contacts": [
{
"email": "[email protected]",
"name": "Jessica Almgren-Bell",
"phone": "312-503-4118",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Emily Jungheim",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Northwestern University Department of Obstetrics and Gynecology",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
},
"state": "Illinois",
"status": "RECRUITING",
"zip": "60611"
},
{
"city": "Baltimore",
"contacts": [
{
"email": "[email protected]",
"name": "Gaelle Massoud,",
"phone": "410-583-2763",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "James Segars",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Johns Hopkins, Division of Reproductive Science and Women's Health Research",
"geoPoint": {
"lat": 39.29038,
"lon": -76.61219
},
"state": "Maryland",
"status": "RECRUITING",
"zip": "21205"
},
{
"city": "Morrisville",
"contacts": [
{
"email": "[email protected]",
"name": "Tifani Panek",
"phone": "773-706-4202",
"phoneExt": null,
"role": "CONTACT"
},
{
"email": null,
"name": "Steven Young",
"phone": null,
"phoneExt": null,
"role": "PRINCIPAL_INVESTIGATOR"
}
],
"country": "United States",
"facility": "Duke Fertility",
"geoPoint": {
"lat": 35.82348,
"lon": -78.82556
},
"state": "North Carolina",
"status": "RECRUITING",
"zip": "27560"
}
]
},
"descriptionModule": {
"briefSummary": "A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist."
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Half of the subjects (200, randomized or not randomized) will receive elagolix 200mg twice a day (BID) and the other half of subjects will receive placebo BID or SOC IVF (200, placebo or SOC IVF). Elagolix or placebo will be taken for a minimum of 60 days before IVF cycle start. For convenience of IVF cycle scheduling, participants may receive up to an additional 14 days of intervention (elagolix or placebo) beyond the minimum 60 days of pre-IVF treatment, such that the last dose of study intervention (elagolix or placebo) is received no more than 24 hours before start of IVF treatment protocol.",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "For participants who agree to be randomized, a computer-generated randomization list will be created by the PREGnant Data Coordinating Center (DCC) and randomization will be performed prior to the first dose of elagolix. Randomization will have random sizes (2, 4, or 6) of blocks and be stratified by site, i.e. whole blocks are assigned to sites. The randomization list will not be available to any person involved in the conduct and evaluation of the trial until the trial is complete and database is declared clean and is released by the DCC. Likewise, treatment allocation information will not be accessible to investigators (except for serious safety concerns), trial staff at the site or central laboratory personnel during the trial.",
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
},
"enrollmentInfo": {
"count": 288,
"type": "ESTIMATED"
},
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "40 Years",
"minimumAge": "18 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT"
]
},
"identificationModule": {
"acronym": "PREGnant",
"briefTitle": "Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp",
"nctId": "NCT06375811",
"orgStudyIdInfo": {
"id": "2000027121_temp",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Live birth rate"
}
],
"secondaryOutcomes": [
{
"measure": "Fertilization rate"
},
{
"measure": "Number of embryos transferred"
},
{
"measure": "Implantation rate"
},
{
"measure": "Biochemical pregnancy rate"
},
{
"measure": "Clinical pregnancy rate"
},
{
"measure": "Miscarriage rate"
},
{
"measure": "Overall pregnancy complication rate"
},
{
"measure": "Gestation age at delivery"
},
{
"measure": "Infant birth weight"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "University of Colorado, Denver"
},
{
"name": "Northwestern University"
},
{
"name": "University of North Carolina"
},
{
"name": "Duke University"
},
{
"name": "Johns Hopkins University"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Yale University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-06-30"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-06-30"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2024-03-16"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "radiotherapy"
}
]
},
"conditionsModule": {
"conditions": [
"Breast Cancer",
"HER2-negative Breast Cancer"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Shijiazhuang",
"contacts": [
{
"email": "[email protected]",
"name": "qimei wang, attending",
"phone": "18633051639",
"phoneExt": null,
"role": "CONTACT"
}
],
"country": "China",
"facility": "The Fourth Hospital of Hebei Medical University",
"geoPoint": {
"lat": 38.04139,
"lon": 114.47861
},
"state": "Hebei",
"status": "RECRUITING",
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "A Single-center, open, prospective study，for analyzing the local recurrence rate, the incidence of incision complications and the aesthetic effect of intraoperative radiotherapy in early breast cancer patients after breast-conserving surgery."
},
"designModule": {
"designInfo": {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
},
"enrollmentInfo": {
"count": 620,
"type": "ESTIMATED"
},
"phases": null,
"studyType": "OBSERVATIONAL"
},
"eligibilityModule": {
"maximumAge": null,
"minimumAge": "55 Years",
"sex": "FEMALE",
"stdAges": [
"ADULT",
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer",
"nctId": "NCT06375798",
"orgStudyIdInfo": {
"id": "2020137",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "LRFS"
}
],
"secondaryOutcomes": null
},
"sponsorCollaboratorsModule": {
"collaborators": null,
"leadSponsor": {
"class": "OTHER",
"name": "Hebei Medical University Fourth Hospital"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2026-11-19"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-19"
},
"overallStatus": "RECRUITING",
"primaryCompletionDateStruct": {
"date": "2026-11-19"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2020-11-19"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
null | false |
{
"armsInterventionsModule": {
"interventions": [
{
"name": "Otago-based (slow rhythmic) exercise group"
},
{
"name": "LSVT BIG-based (large amplitude) exercise group"
}
]
},
"conditionsModule": {
"conditions": [
"Elderly People",
"Nursing Homes"
]
},
"contactsLocationsModule": {
"locations": [
{
"city": "Istanbul",
"contacts": null,
"country": "Turkey",
"facility": "Haliç University",
"geoPoint": {
"lat": 41.01384,
"lon": 28.94966
},
"state": "Eyüpsultan",
"status": null,
"zip": null
}
]
},
"descriptionModule": {
"briefSummary": "The aim of the study is to compare slow rhythmic exercises with large amplitude exercises in elderly people"
},
"designModule": {
"designInfo": {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "QUADRUPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR",
"OUTCOMES_ASSESSOR"
]
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
},
"enrollmentInfo": {
"count": 70,
"type": "ACTUAL"
},
"phases": [
"NA"
],
"studyType": "INTERVENTIONAL"
},
"eligibilityModule": {
"maximumAge": "80 Years",
"minimumAge": "65 Years",
"sex": "ALL",
"stdAges": [
"OLDER_ADULT"
]
},
"identificationModule": {
"acronym": null,
"briefTitle": "Two Different Exercise Methods in Geriatrics",
"nctId": "NCT06375785",
"orgStudyIdInfo": {
"id": "LSVT-BIG vs Otago",
"link": null,
"type": null
},
"secondaryIdInfos": null
},
"outcomesModule": {
"otherOutcomes": null,
"primaryOutcomes": [
{
"measure": "Timed Up &Go Test"
},
{
"measure": "Performanz Balance System"
},
{
"measure": "Functional Reaching Test"
},
{
"measure": "Six Minute Walking Test"
},
{
"measure": "Tinetti Balance and Gait Assessment"
}
],
"secondaryOutcomes": [
{
"measure": "Activity-Specific Balance and Confidence Scale"
},
{
"measure": "Five Times Sit to Stand"
},
{
"measure": "Montreal Cognitive Assessment Test"
},
{
"measure": "KATZ Activities of Daily Living Scale"
},
{
"measure": "Clinical Frailty Scale"
}
]
},
"sponsorCollaboratorsModule": {
"collaborators": [
{
"name": "Fenerbahce University"
},
{
"name": "Istanbul Galata University"
},
{
"name": "Biruni University"
}
],
"leadSponsor": {
"class": "OTHER",
"name": "Halic University"
}
},
"statusModule": {
"completionDateStruct": {
"date": "2024-03-01"
},
"lastUpdatePostDateStruct": {
"date": "2024-04-23"
},
"overallStatus": "COMPLETED",
"primaryCompletionDateStruct": {
"date": "2023-06-01"
},
"resultsFirstPostDateStruct": null,
"startDateStruct": {
"date": "2023-03-01"
},
"studyFirstPostDateStruct": {
"date": "2024-04-19"
}
}
}
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.